Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Faron Pharmaceuticals, R&D day 2026

By Inderes10/8/2026, 12:00 PM
Faron Pharmaceuticals

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Juho Jalkanen
00:00 - 01:54

Good day, everyone, and welcome to the Faron Pharmaceuticals R&D Day. My name is Juho Jalkanen. I am the CEO and one of the founding members of Faron Pharmaceuticals. For those new to the story, Faron Pharmaceuticals is a leading biotech in the fight against higher-risk myelodysplastic syndromes. Higher-risk myelodysplastic syndromes are one of the true unmet needs in oncology. Also known as the pancreatic cancer of hematology, we are listed on both the London Stock Exchange and the Helsinki Stock Exchange. Standard corporate disclaimer applies as we will be making forward-looking statements; it is our pleasure today to bring a comprehensive agenda on our activities and thinking. The first part will concentrate on our lead program in higher-risk MDS and a slight update to the schedule. We will start with Professor Zeidan due to his tight conference schedule. The second part concentrates more broadly on the pipeline, the market opportunity, and the company vision. Also a bit on housekeeping. We will have a larger Q&A session at the very end, but that is for Faron Pharmaceuticals management. If you have specific questions for an external expert like Professor Zeidan, please type in your message and we will have a short Q&A after every external speaker so that we can let them attend to their daily duties. So again, specific Q&A specifically for an expert, otherwise a large Q&A at the end. That is all from me for now. Your host and I will give the floor to our esteemed chairman, Mr. Tuomo Pätsi.

Tuomo Pätsi
01:56 - 06:16

Thank you and welcome everyone also on my behalf. Thank you for joining this event. So we have a great program today that you have just shared, and I hope it addresses the request from many of you who have asked for more thorough information about our science and our R&D plans. At Faron Pharmaceuticals. I am personally especially excited about our lead opportunity. So, bexmarilimab in high-risk myelodysplastic syndromes. Early in my career, I held executive roles at some of the leading global biopharma companies, Amgen, Celgene, and Seagen. And these are all companies that are involved with developing and commercializing cancer therapies and also hematological cancers like AML and Myelodysplastic syndromes. Over the 35 years that I have been in the industry, we have seen a lot of progress in many cancer indications, also in hematological cancers, but there are some where the progress has been truly limited and high-risk Myelodysplastic syndromes is one such indication. The last significant improvement was probably the introduction of hypomethylating agents like azacitidine, and I was lucky to be part of launching that product internationally while I was at Celgene, but that was already 17 or 18 years ago. So it is definitely time now for the next breakthrough in this indication, and we hope that we will be able to build on the current standard therapy and further improve the outcomes for patients. By adding bexmarilimab, we can move on to the next slide, please. So, 2026 has been, you could call it, a clarity-building year for Faron Pharmaceuticals. We now have a clear, focused plan. The team is focused on executing this plan. With longer follow-up of our BEXMAB study, we have continued to see excellent results with Bexmarilimab in both first-line and relapsed/refractory high-risk myelodysplastic syndromes, and that has given us and clinical experts across the world the conviction to move Bexmarilimab now to the next phase of clinical development. There were also some external events late last year that impacted our plans. Namely, the failures of other product candidates in this indication. Rather than repeating what was not working in terms of study design, we took these insights and modified our development plans accordingly. We are now focused on starting a randomized, double-blind Phase 2b trial as the next step. This will be a comparison of Bexmarilimab plus azacitidine to placebo and azacitidine. And it will be in first-line high-risk myelodysplastic syndromes. We will hear more about this study and the plan shortly, along with how we intend to execute it. We raised €40 million through a rights offering earlier this year, and now we have the funding to reach the readout of this randomized trial. And obviously, this will be a major value inflection point for the company. We have a clear plan. We have the funding needed for the next milestone. We have a great team at Faron Pharmaceuticals. So we have strengthened the team recently. And very importantly, we have the support of the experts in the world's top research centers. And let's not forget, in addition to myelodysplastic syndromes, we have our program in solid tumors, and we will be hearing more of this as well. As we recently announced, we have already initiated the first patients in these combination studies. It is an exciting year, and we have an exciting program ahead of us today. Let's now move on to our first expert presentation, which will be by Professor Amer Zeidan from the Yale School of Medicine; he is broadly recognized as a leading global expert in myelodysplastic syndromes, and he will share more details on the planned BEXERA study and the evolving myelodysplastic syndromes treatment landscape. So over to you, Professor Zeidan.

Amer Zeidan
06:18 - 24:20

Thank you so much, Tuomo, and it is a pleasure to be here with you today. A couple of disclaimers: these represent my own opinions and not those of my employer. I have consulted for Faron Pharmaceuticals, but I am also a little bit under the weather. I apologize for my voice. And there's a big thunderstorm behind me. So if you hear thunder, that is what it is. Can we go to the next slide? So, what I am going to do today is I am going to talk about myelodysplastic syndromes as a disease and the challenges in terms of drug development, and then talk about the evolving treatment landscape, in particular, some of the most recent phase 3 trials and their failures, and how we have been working in the field in general. I have been working closely with the Faron Pharmaceuticals team to design the trial in a way that we have learned a lot from the previous trials so that we can optimize the chance of success in the BEXERA trial and, hopefully, in the subsequent phase 3 trial. Next, please. Next. So, myelodysplastic syndromes, many of you have probably been following these calls, know the disease by now, but myelodysplastic syndromes is a cancer. It is a form of blood cancer. It is associated with bone marrow failure and therefore symptoms of anemia, neutropenia and thrombocytopenia leading to infections, bleeding and life-threatening complications. And while many patients with MDS will not progress to AML. They still often will die from complications related to the bone marrow failure. But still, one third of patients will progress to acute myeloid leukemia, and the survival with high-risk MDS really has been quite limited, as I am going to show you in the next slides. Next, please. Next. So as you just heard from Tuomo, the standard of care for MDS has not changed significantly over the last 20 years in any substantial fashion, and bone marrow transplant continues to be the only potential way to get a cure. However, with the median age of MDS patients being in their early to mid-70s, and with many patients having comorbidities related to age, most patients with MDS are not candidates for transplant, and real-life analyses have actually suggested that less than 5% to 10% of patients undergo transplant. Therefore, the mainstay of treatment has been hypomethylating agents with Azacitidine and Decitabine for a long time in the US. Both of those drugs are approved, plus an oral version of Decitabine called Decitabine and cedazuridine. While in many countries around the world, only Azacitidine has been approved because it has been the only drug to show a survival improvement in a randomized Phase 3 trial. Now, in the relapsed/refractory setting, there are really no approved drugs outside of an IDH1 inhibitor that is approved in the US based on single-arm Phase 1 data. But that really applies to less than 5% of patients with MDS who have this particular mutation. So for the vast majority of patients, there are really no treatment options. We know that intensive chemotherapy can be used in younger patients who have excess blasts. But this is generally used as a bridge to transplant and not as a definitive treatment by itself. And while hypomethylating agents have helped patients, there are a number of problems. First of all, less than half of the patients will achieve a response, so more than half of them will not have a response. When you look at complete response, it happens in 20% or less of patients. So 80% will not achieve a complete response. And even those who respond typically will relapse, usually within 1 to 1.5 years. The median survival with hypomethylating agents is limited to around 18 to 20 months, as I am going to show you in some of the real-life studies, but importantly, many patients with MDS, even if they respond, will eventually progress. So everybody will progress after some time on HMAs. And once they progress, the median survival is less than six months. And we don't have a reliable way of predicting responders to hypomethylating agents. So this really leaves a significant unmet need for almost everyone. With MDS, including patients who receive hypomethylating agents with the goal to increase the rate of complete response, but also to deepen the response, improve the quality so that it's more durable, and ideally reduce transfusion burden and improve survival. These are the main goals of treatment. Next, please. So this paradigm for the treatment has not really changed over the last 20 years. As you can see, it is a much simpler paradigm compared to other diseases like myeloma, AML, or CLL. Here, if the patient is a transplant candidate, the recommendations go to transplant. But again, this is only 5% to 10% of patients. Sometimes we use bridging therapy. There are controversies regarding this. We can discuss that later. But for the vast majority of patients who are not transplant candidates, the standard of care has been hypomethylating agent monotherapy. Although a number of drugs looked at combinations and we are going to show you some of the data. But unfortunately, all of them have failed. And in the relapsed/refractory setting, as I mentioned, only one IDH inhibitor has been approved for only 5% of patients who have IDH1 mutations. Next, please. So while the randomized AZA-001 study showed a median survival of 24 months, which was significantly longer than the 15 months with conventional care regimens. In real-life analysis, it has been very difficult to replicate those 24 months with Azacitidine. Here you can see three different sets of real-life analyses that we have done, including pooling data from a number of frontline high-risk MDS studies. And what you can see is that the median survival ranges somewhere between 12 months in older patients, all the way to 19 months for patients who were included in clinical trials. So even worse than what was seen in the randomized clinical trial, and clearly showing the need for improved therapies. Next, please. Now, you will be hearing a lot during this session about bexmarilimab, but the activity in combination with azacitidine I think has really demonstrated very promising responses. And in this slide, you can see a summary of the top-line data from the study that looked at patients. We studied 21 patients in the frontline setting. And the response rate using the traditional 2006 criteria was 45%, using the IWG 2023 criteria, which emphasizes count recovery. The CR rate is 41%. Many of those patients, 57% who were transfusion dependent, became transfusion independent, which is an important clinical benefit for patients. And 67% of patients achieved MRD negativity using local assays. The median duration of response for CR/CRi patients was 16 months, and most of the patients achieved some blast reduction. As you can see in this latest data cut from 2026. Next, please. In the relapsed/refractory setting, we also studied 33 patients. And again, this is a setting which, as you may remember, is very difficult. There are no approved drugs for most patients. Median survival is around 4 to 6 months. So when we give azacitidine with bexmarilimab, it does seem that bexmarilimab was sensitizing patients to azacitidine. So we saw complete responses and partial responses in 12% of those patients. The overall response rate was 64%. Some of those patients were able to be bridged to transplant, which again is the only way to try to cure these patients. But importantly, the median survival was around 14.5 months in the relapsed refractory setting, which again in direct comparison, is a small study. But this looks much better than the expected six months after treatment failure. And I think this, given that these patients were already refractory to, I think this provides very good proof of concept about the additional activity of Bexmarilimab when it's combined with it, both in the front line, but also in the relapsed refractory setting. Next, please. The safety profile of the drug in Myelodysplastic syndromes patients, as I mentioned in the beginning, is favorable, considering they are older patients. Most of them are in their 70s. They have a number of comorbidities. So they are frail patients. They often do not tolerate a lot of additional myelosuppression or combination drugs that can induce significant toxicities. Here with Bexmarilimab, we saw a very good safety profile. The hematologic adverse events were largely what you see with azacitidine by itself, although, of course, in a single-arm study, it is always difficult to attribute results 100%. But overall, given the solid tumor data, it did not suggest myelosuppression with Bexmarilimab. And historically, when you compare these data to azacitidine by itself, it does not seem that hematologic toxicities are increased with the combination. But importantly, Bexmarilimab has low rates of infusion reactions, and no patients died from the drug. So far in the clinical trials, the incidence of infusion-related reactions and immune-related adverse events has generally been low, and the drug is well tolerated. Next, please. Here you can see a comparison to the historical azacitidine data. As I mentioned. So it does not seem that the rates of thrombocytopenia and neutropenia look worse. Actually, it does look a little bit better. But of course, this is an indirect comparison with a historical control. But I think this gives reassurance that it's unlikely that adding Bexmarilimab to Azacitidine is leading to worsening hematologic toxicity. Next, please. Now, of course, these were all single-agent or single-arm trials, both in the frontline and the relapsed/refractory setting. So we need to go into a randomized setting. And we have spent a significant chunk of the last one and a half years working with Faron Pharmaceuticals, but also with the regulators, to develop a randomized trial program, while also learning from the multiple failures that we have seen in combining Azacitidine with other drugs. You can see here a listing of some of these trials with other drugs, including. Venetoclax. Sabatolimab. Magrolimab. Pevonedistat, APR-246, and Tamibarotene. And you can see that they have used different endpoints, but the shared feature is that none of them have reached their primary endpoints. Next, please. So, what are the lessons? I think one lesson is overestimation of the treatment effect. This is something that we have seen. People are often too optimistic based on the initial small data in terms of the effect size. And I think when you power your randomized trial to a very large treatment effect difference, which is not replicated on the ground, that will lead to missing the primary endpoint. Also, there was not a lot of understanding of the subgroup analysis and the best dose and the biomarker selection for patients. All of these have suffered across a number of trials. Overall survival I think can be sometimes tricky in these early phase trials because there are different baseline disease characteristics. And this means that what you try to power for can be challenging, depending on how many patients go to transplant and the different operational and statistical assumptions; there has been some trial or result variability by region and differences in the supportive care. For example, the use of antibiotic prophylaxis, as well as the robust assessment of responses, which sometimes can be tricky. So it really needs sponsor involvement in making sure those responses are reflecting accurate results. And finally, I think trying to improve the design of the trial to account for variability that might occur, for example, allowing an adaptive design to re-estimate the sample size based on evolving data, as we will talk about later. Next, please. So we implemented all of these lessons in the design of the randomized Phase 2 trial, which is a dose-finding study. So it will involve Bexmarilimab at two different doses, 1 mg/kg and 3 mg/kg, combined with Azacitidine versus Azacitidine with placebo. And this will allow us both to establish the contribution of the component, but it would also allow us to select the best dose to move forward. The effect size that was assumed in this trial was realistic. So a small effect difference will allow the trial to move forward in terms of dose selection. The trial will stratify by things that are important to patient outcomes and that have been causing some problems when they are imbalanced in other studies such as TP53, blast percentage, and IPSS. I think this study will also provide a lot of understanding about the differences in dose activity, as well as PK and PD. Dose intensity and, hopefully, biomarker predictors and subgroup analysis will inform the selection of patients for the randomized Phase 3 trial. Next, please. So with that all in mind, we met with the regulators and I think we discussed the different options. The program moved towards the BEXERA trial, which is a randomized phase 2b trial. You can see here, which will, as you just heard, already enroll patients and is activating in a number of centers, including my center at Yale. And here, 90 patients will be randomized, 30 patients per arm, to two doses of bexmarilimab versus placebo, all of them combined with Azacitidine. And that will inform the design of the subsequent confirmatory trial. Next, please. Of course, this trial will use a complete response plus CR equivalent as a primary endpoint and will also introduce analysis focusing on dose selection, as well as other analyses looking at event-free survival and safety. Next please. This will be a global study. Many sites, as you can see, 35 sites across the US, Europe, and the UK, which will allow for rapid accrual so that the results can be available in late 2027. And you can see here some of the sites from the US that will open the trial, next please. And this provides more details about the trial. I would mention that most of the sites that opened the BEXMAB, the phase one trial, are proceeding with the phase two. I think this reflects the confidence of the investigators in the drug and the good experience, but it also helps with the logistics. And since many of those investigators, including myself, have worked with Faron Pharmaceuticals in the past, and other sites were selected that have extensive experience with myelodysplastic syndromes to optimize the conduct of the study. Next, please. So in summary, I think there is a significant high unmet need in all patients with MDS, specifically high-risk MDS, including the frontline as well as the relapsed/refractory setting. HMAs and transplant continue to be standard of care, but most patients will not undergo transplant, and HMAs have limitations. I think the BEXMAB study of bexmarilimab has shown very promising safety and efficacy data, including durable CR in 45% of patients, and we saw good survival data in the relapsed/refractory setting as well as good data in TP53. And therefore, I think we are ready to validate that in a randomized, placebo-controlled study of two doses of bexmarilimab combined with azacitidine versus azacitidine with placebo. To understand the contribution of each component, but also to understand the dose selection, to inform the subsequent phase three trial. And we have used the learnings from previous failed phase two and phase three randomized studies to design the BEXERA trial in a way that will optimize the chance of success, including discussions with the FDA about the use of endpoints, which will be complete CR here, plus CR equivalent and the durability of the CR and stratifying the patients for important factors such as IPSS risk, blast percentage and TP53 status. And I believe this is the last slide. Happy to take any questions.

Juho Jalkanen
24:23 - 24:29

Wonderful talk. I have received a message that we have some questions from the audience and we will be hearing them.

Unknown 1
24:29 - 24:50

Thank you for the excellent presentation. There are multiple questions, but we know that you have limited time today. So let's kick off. There is a lot of discussion about safety. How important is the safety in this setting and in this patient population when combining with Azacitidine?

Amer Zeidan
24:52 - 25:31

Yes, this is very important because we have seen two things. One is that most of those patients are in their 70s, and they are frail and have comorbidities. It is very easy for these patients to receive a drug combined with Azacitidine that causes myelosuppression, which can lead to significant problems. We have seen some of that with Venetoclax. We have seen some of that with Magrolimab. And that really can derail the trial. So having a drug that is easy to combine and that can be administered on a chronic, long-term basis without causing high rates of discontinuation is very important. So I think this is critical in any drug design for high-risk Myelodysplastic syndromes.

Unknown 1
25:32 - 25:47

Thank you. Based on the results seen so far, especially on the last line, do you think that we can establish a contribution of each agent from these results?

Amer Zeidan
25:48 - 26:33

I think so. It is always difficult to make solid conclusions from Phase 1 studies with a relatively limited number of patients. But I think all that we have seen in terms of the efficacy and safety from the trial, as well as my own personal experience with the drug, looks very promising. I think we are very well positioned to do the phase two randomized trial, which, as I mentioned, is designed in a way to optimize the success of the trial so we don't end up in a situation where you have a drug that works, but because the trial is not very well designed, it leads to problems. So I think here the trial is really designed to show the full benefit of the drug.

Unknown 1
26:34 - 26:46

Thank you. And what makes you confident about Bexmarilimab or what gets you excited? Is it the TP53 safety profile, or what makes you confident about bexmarilimab?

Amer Zeidan
26:47 - 27:32

I think it is all of them. I think the tolerability in the frontline setting, the early activity we see in TP53, the safety profile, but also importantly, we are seeing some evidence of pharmacodynamic changes like some immune activation suggesting the mechanism of action of the drug, some early signals that you could predict responders using T-cell subgroup or subset analysis, but also the survival in the relapsed/refractory setting of 14 months when only 20% of them went to transplant. This is quite good. So I am really hopeful and look forward to seeing these results replicated in the randomized study.

Unknown 1
27:33 - 27:47

Thank you. And then for the last question, based on your experience and recent activities in the field, do you think that bexmarilimab is the one that can succeed or show a positive result?

Amer Zeidan
27:48 - 28:28

Yeah. I am someone who is optimistic by nature. And I certainly think all that we have seen so far with the drug is very positive. Ideally, from a patient perspective, we want not only one drug but multiple drugs. I am hoping there will be a number of drugs succeeding and helping our patients. But for Bexmarilimab in particular, I think the data really looks as good as you can within a single-arm Phase 1 study. And of course, the confirmation will be through randomized studies which we are going to do. So I think we will find our answers hopefully by the end of next year.

Unknown 1
28:29 - 28:31

Thank you. And over to you. You hope.

Juho Jalkanen
28:32 - 29:16

Thank you, Professor Zeidan. We will let you go. Have a wonderful and productive day. And as you mentioned, we are here to seek the truth. And that is what we are going for. Thank you. And next, a great segue after that is, I am going to invite our Chief Scientific Officer, Dr. Maija Hollmén, to the stage because she receives all these samples from the ongoing trials, analyzes them, and sees what is going on in these patients. It is something that Professor Amer Zeidan also alluded to. What we are seeing happening in these patients really validates the clinical activity of this drug. But over to you.

Maija Hollmén
29:17 - 44:51

Thank you. Hi everyone and welcome also on my behalf. So as you mentioned, I will be talking about what we know about bexmarilimab in myelodysplastic syndromes. But first, I want to briefly go over the basics of cancer and how it grows. For cancer to grow, it needs to gain several functions known as the hallmarks of cancer, which include enabling replicative immortality, genomic instability, and mutation. They acquire mutations so that they can achieve these goals. They have deregulated metabolic functions. They have tumor-promoting inflammation within the tumor microenvironment. They need to induce angiogenesis to grow bigger than one cubic millimeter. And so you can see all of these functions on the left-hand side of your screen. But what is interesting, and the current state now, is that pharmaceutical companies are trying to target these hallmarks with different drugs. So they are developing drugs to each of the hallmarks separately. But I now want to introduce you to something that we are trying to do. And it's in the middle of the graph. You can see the immunosuppressive myeloid cell. So, what is known about these cells is that they can support nine out of the ten hallmarks that I am representing here now. They are very powerful cells in suppressing and supporting tumor angiogenesis, metastasis, and inflammation that promotes even more genomic instability. So what can we do utilizing these cells to promote anti-tumor immunity and tumor destruction? So we propose that we can reprogram these myeloid cells to actually activate anti-tumor immune responses and therefore reduce tumor growth and impair metastasis events that are normally seen and that eventually kill tumor patients. So there you can see on the right-hand side, if we can then reprogram these macrophages to a pro-inflammatory anti-tumor myeloid cell, we can overcome all of these nine hallmarks, except for the enabling replicative immortality that the cancer cells have themselves. But that, of course, if you reduce all of the other hallmarks, you can really gain super powerful effects on the tumor growth itself. So going back to our target and knowing what our target does based on preclinical and translational research that we have gained over the years, we look at what the macrophage normally does. This is now representing a macrophage that is expressing Clever-1, which is the target that bexmarilimab binds to, scavenging acetylated LDL and oxidized lipids on the cell surface to take them inside the cell and induce these lipid nuclear receptor signaling pathways that promote tolerogenic macrophage subsets. So basically, I can say that whatever the macrophage is eating, it is hiding from the immune system. And this can be seen as an increased secretion of IL-10 and regulatory T cell formation. What is also interesting within these macrophages, as shown in the left-hand corner, is that when macrophages eat different endogenous substances, they take them very rapidly into phagolysosomes. So they acidify these lysosomes and degrade everything that they are eating, effectively hiding it. Now, when we target these macrophages with bexmarilimab, it binds to Clever-1, inhibiting the scavenging of, for example, these oxidized lipids. And they are not taken inside the cell. That then impairs the induction of these tolerogenic macrophages. While doing this, Bexmarilimab can impair the acidification of these lysosomes. These lysosomes are contributing to the promotion of antigen presentation via this impaired endosomal acidification, so that it has time to present the antigens to the immune system. It also activates NF-kappa B signaling, producing TNF-alpha, IL-12, CCL3, CCL4, CCL5, and CXCL10, which are important molecules for supporting anti-tumor immune responses, for example, T-cell activation towards cancer cells. And there you can see that leads to an expansion of activated effector T cells. So why is this important in Myelodysplastic syndromes? Because I want to highlight now that myelodysplastic syndromes is not only a clone of malignant cells. Also, these are myeloid cells that have gained malignancies. But one needs to always remember that malignant cells are within their tumor microenvironment. And now we're discussing the bone marrow tumor microenvironment, where you have a suppressive myeloid compartment that is supporting tumor growth. And that is suppressing the effective T cell response that you would normally have against the tumor. What you also get, of course, is that if you have this clonal expansion, you get dysfunctional hematopoiesis that causes all the effects that Amer Zeidan was just presenting, which are anemia, neutropenia, and thrombocytopenia that is really severe, and people get bleeding, infections, and so forth. To understand this in context, I will go through what we know about Clever-1 and how it can support these activities for a better outcome for the patient. I want to briefly tell you about Clever-1 and what we know about Clever-1 in myelodysplastic syndromes. So, basically, Clever-1 is a scavenger receptor expressed also by leukemic myeloid cells. In addition to the normal monocyte macrophage subsets, you can see on the right-hand side a plot where each dot represents one patient sample, and the more red that patient sample is, the higher the expression of Clever-1 is in these samples. So you can clearly see that you get a lot of red. AML is super red. Myelodysplastic syndromes are as well. So they are very good indications for targeting Clever-1. So, Clever-1 is involved in receptor-mediated endocytosis. I was just explaining. It also regulates leukocyte trafficking, inhibits T cell activation, and promotes tumor growth, which has been demonstrated by various publications over the years. It is also known that high-level expression in cancer is associated with poor prognosis and contributes to treatment resistance. So it is a very important factor regulating tumor growth and metastasis. So now going back to HR-MDS and what we think is a very good approach. Why BEXMAB works so well is that it has a dual mode of action because Clever-1 is expressed on the monocyte myeloid compartment but also on the blast cells. So by Bexmarilimab, you can target both of these arms, which on one hand induces immune activation by presenting the antigens to T cells and therefore affecting adaptive immune activation and killing of blast cells. On the other hand, in point number two, BEXMAB works by binding to Clever-1 on the blast cells. By binding to Clever-1 on the blast cells, it can impair their metabolic parameters and sensitize cells to azacitidine, for example, as it is now shown. This is data from the bone marrow of the patients that were treated with the combination of bexmarilimab plus azacitidine in the Phase 1/2 study. And now on the left-hand side, you can see HLA-DR expression on monocytes and blast populations that was measured from the patient bone marrow. HLA-DR. HLA-DR is an antigen-presenting molecule that activates CD4 T cells. And here you can see that on the monocytes, Bexmarilimab is increasing the HLA-DR expression. expression on the responding patients. It is very interesting that you can activate the immune system and get a response from the combination therapy. What is also happening, interestingly, is that the absolute numbers of CD8 T cells increase in the bone marrow, and CD8 T cells are the killer T cells that kill the tumor cells very effectively. So by increasing these numbers, you can actually affect how the blast cells are killed. And on the right-hand side, you can see that during the treatment cycles, the absolute numbers of T cells increase significantly. When you increase the doses of bexmarilimab. But going back to now, we are looking at the metabolic changes that we see in the blast cells. So what we see in the clinical trial is that there are some indications that BEXMAB would enhance Azacitidine treatment. So what we have done in the lab is that we have analyzed, for example, first, how does Clever-1 interact with other molecules in the cell. So in this figure here, you can see the whole interaction. An interaction map of the proteins that are interacting with Clever-1 inside the cell. So you can see it is quite a big interaction map. Now, when we treat these cells with bexmarilimab, you can see that there are no longer that many proteins interacting with Clever-1. If we now look at what functions these impaired interactions have on the cell. You can see that these cells are stressed. They are increasing their mitochondrial RNA granules to produce mitochondrial respiration. And this can be seen in the D part, where you can see impaired oxidative capacity. So the mitochondria cannot produce energy via oxidative phosphorylation. This then translates to the viability arm in the e-part, where you can see that a cell that is normally Azacitidine-resistant becomes sensitive to Azacitidine if you add Bexmarilimab to these cells. This is basically telling us that BEXMAB is priming the mitochondria for standard-of-care treatment so that they can more reliably exhibit impaired viability after standard-of-care treatment. I want to also highlight, as Amer Zeidan said, that BEXMAB was a combination trial. It is very difficult to determine what Bexmarilimab adds to Azacitidine treatment. So when we look at this figure here, we have measured target engagement of bexmarilimab on soluble Clever-1 in an ELISA assay. This means that we can see how much of our drug is binding to Clever-1. This figure shows that patients who achieve a complete response to the combination treatment demonstrate higher target engagement of bexmarilimab on Clever-1. And this suggests to me that our drug is actually doing something, because the complete response is associated with increased target engagement, which is very hopeful. And we want to, of course, study this further in the BEXERA trial. Then there was this interesting figure or data on the left-hand side, showing that there are some indications that the side effects in neutropenia, thrombocytopenia, and anemia would be reduced in the combination compared to Azacitidine alone. This is interesting because when we examine the bone marrow samples of the BEXMAB patients who were treated with the combination. You can see here two UMAP plots on the right-hand side of this screen. This plot shows single-cell RNA sequencing data from five patients who responded to the combination. That achieved a response to the combination, and each dot represents one cell. The closer the cells are together, the more similar they are in this map. We can annotate these cells, and you can see that we have annotated them as monocytes, granulocyte-myeloid progenitors, and blast cells. And this left-hand side UMAP shows the patient status upon entering the trial. We took a bone marrow sample of the patients before they received the combination therapy. Now when we look at the same map, you can see after three cycles of treatment, you get a robust reduction of cells in the monocyte lineage. And these markers are telling us that these cells are very immunosuppressive and not ideal for the tumor microenvironment. So we can reduce these cells significantly by the combination. But what is also interesting is that you can see in the far right-hand corner. An increase in eosinophils. Basophils. Mast cells. Mast cells, erythroid precursors, and megakaryocyte precursors. So they are increasing with the treatment. This was after three cycles. So if we want to. We went back to the lab and asked whether BEXMAB can promote hematopoiesis by itself. We performed this experiment to determine if this effect on the progenitor populations is not coming from the combination, but is actually coming from bexmarilimab alone. We performed this colony-forming assay. So you can see here on the lower left-hand side these colonies that we are counting from this colony-forming assay. You have small, medium, large, and mixed colonies. And you can see here that adding bexmarilimab into these colonies, compared to isotype control, we see a significant increase in the colony formation of megakaryocyte colonies and different mixed colonies. That indicates to us that Bexmarilimab is affecting these hematopoietic progenitor cells metabolically, so that it can induce their proliferation by itself. I want to conclude with the exciting scientific findings that we have observed from the lab and from the patient samples, showing that BEXMAB combined with azacitidine induces very broad hematopoietic and immune reprogramming in the bone marrow as it activates progenitor populations, enhances lineage commitment, and promotes niche normalization. It increases complementary epigenetic and metabolic pathways in blast cells, and these findings support the therapeutic potential of this combination in myeloid malignancies, which we are evaluating in the BEXERA trial to see the difference in placebo-controlled settings to define how bexmarilimab is really working. So that was my last slide, and I'm happy to take questions if there are any.

Juho Jalkanen
44:53 - 45:10

Thank you. Thank you. I am going to take this opportunity myself, if I may, because I have learned that you are a macrophage expert. And macrophages seem so thrilling and fascinating. But why do you love macrophages? Why are they so fascinating for you?

Maija Hollmén
45:11 - 45:39

For me, the first time I actually became fascinated by them was when I understood that half of the tumor mass can consist of macrophages. It was interesting to me: what were they doing there? And then I learned that people are calling them the Swiss Army knife of the immune system. And it fascinates me that they can do anything they like. They have the possibility to become everything and perform many, many tasks. So that's why they're so fascinating. To me.

Juho Jalkanen
45:40 - 45:48

It sounds like a tricky cell to target if it is a Swiss Army knife. So why is Clever-1 such an important target on macrophages then?

Maija Hollmén
45:48 - 46:08

So, of course, there are many scavenger receptors and many checkpoints on macrophages. But what we have learned from the lab is that Clever-1 has a really non-redundant function in macrophage immunosuppression. Okay. That is why we believe that by targeting Clever-1, we can gain multiple functions within the macrophage that support anti-tumor immune responses.

Juho Jalkanen
46:09 - 46:27

Okay. That is an important thing because what I have learned from the field is that since there have been failures in macrophage targeting, people are discussing whether we should use two or even three macrophage targets? What are your thoughts on that?

Maija Hollmén
46:28 - 47:04

Well, of course, it might be beneficial if you target macrophages from different angles. Let's say one is inducing phagocytosis and we are inducing antigen presentation. This, of course, might be a good approach, but I also want to emphasize that I think we should also consider other cell types, like macrophage and T cell activators, so that we get both components activated. So I think we still need to learn a lot, but I believe Clever-1 is a very good target due to the fact that it is regulating many of the functions that are needed for the anti-tumor response.

Juho Jalkanen
47:04 - 47:06

So Clever-1 alone could be enough for macrophages.

Maija Hollmén
47:06 - 47:07

Yes. Yeah.

Juho Jalkanen
47:08 - 47:10

Okay. Well, we'll get to the bottom of that.

Maija Hollmén
47:10 - 47:10

Yeah.

Juho Jalkanen
47:10 - 47:58

Thank you, Maija. Don't worry. Audience. Maija will be back for the management Q&A. Next, I want to take this opportunity to share the stage with an important partner for us. And it is Blood Cancer United and their Therapy Acceleration Program. Not that many may be aware of the good and important work. Blood Cancer United does. So we wanted to give them the chance to put the word out on what they do and how they have been working with us to take the TAP program forward? So with these words, I give the floor to Dr. Blaine Robinson, VP of the TAP program. Over to you, Blaine.

Blaine Robinson
47:59 - 68:58

Thanks so much, Juho. It is good to see you. Thank you so much for the opportunity to join Faron Pharmaceuticals' R&D Day today. It is a wonderful pleasure. As you mentioned, I am the Vice President of our Therapy Acceleration Program, or TAP for short. It is Blood Cancer United's venture philanthropy initiative, and I have worked with this organization for more than 15 years, all as part of the TAP team. Before that, before coming to Blood Cancer United, I worked in a pediatric leukemia laboratory at the Children's Hospital of Philadelphia. So my connection to blood cancer really goes back more than 20 years. I will first start today with our mission and the research programs behind Blood Cancer United, and then use myelodysplastic syndromes as a model to show how our mission can inform some of our commitments. I will introduce our Therapy Acceleration Program investment and collaboration model before turning to the patient need. In the history of our partnership with Faron Pharmaceuticals, as you alluded to. My purpose today is not really to position one company over another, but really to show how a mission-driven organization like ours decides where to accelerate development. So before I speak about the Therapy Acceleration Program and myelodysplastic syndromes, I would like to tell you a little bit about our nonprofit and why we are here at an R&D day. Next slide, please. So many of you may know us by our former name, the Leukemia & Lymphoma Society, or LLS. We recently rebranded about a year ago as Blood Cancer United, really to better reflect the full breadth of our patients' families, all the different blood cancer diseases, and the communities that we serve. Our name has changed, but our mission really has not. Our vision still remains a world without blood cancer. Our mission remains to cure blood cancer and improve the quality of life for all patients and their families. We do three things at the Blood Cancer United Organization. We pioneer life-saving research worldwide. We help empower patients, caregivers, and providers with free information and support services, and we help amplify the voices of patients seeking access to quality, affordable care. For this audience today, research is the reason I am here. But the other two pillars are really what make our perspective on any development program different from any other foundations or investors. Next slide please. Our organization, Blood Cancer United, formerly Leukemia Society of America and then Leukemia and Lymphoma Society, was founded more than 75 years ago, really with the goal of finding a cure for leukemia. But today, we have become the world's largest nonprofit health organization dedicated to blood cancer research worldwide, providing education and patient services, and leading policy and advocacy efforts, especially in the United States. We have helped fund the vast majority of breakthroughs in blood cancer research over that period. Next slide please. This slide shows seven decades of what research investment has helped produce. We have seen dramatic improvements in five-year relative survival in many of the major classifications of cancers from the 1960s to today. And it has been especially accelerated by the explosion of new therapies over the past 20 years. It is a really exciting time to be in this blood cancer space and drug development. For example, in myeloma, only 12% of patients survived five years in the 1960s, compared to over 60% today. The results are very similar to leukemia. And patients with non-Hodgkin's lymphoma have even better outcomes. Over 90% of patients are now surviving five years or more. Recently, our organization led a specific analysis, and it was published in Blood Advances just this past month. We have conducted this analysis, which puts this progress into more human terms than just these numbers. And what we have concluded is that over these years, advances in blood cancer treatment have helped save nearly 26 million years of life. That is really what our organization is about: saving life years. That's decades of science translated into something every patient and family can understand. More time together. So these are obviously all the field's numbers, not ours alone. It takes our organization, along with all the other organizations and companies in the world. But it really reflects the breakthroughs that have changed what's possible for patients. Really, there are two well-known examples to help make this progress a little more tangible. For example, a drug called Gleevec changed the outlook on chronic myeloid leukemia by turning a once-fatal disease into one that many patients can manage for many years with targeted therapy. In addition, rituximab is another good example that really reshaped B-cell lymphomas and other CD20-positive diseases, helping more patients achieve durable remissions. And really, that type of track record is why a nonprofit like us belongs in a conversation about drug development. And it is also a reminder that there is still much more work to do. Next slide please. Shown here is a snapshot of many different numbers and our contributions to research. A couple I wanted to point out. So as I mentioned, we're the largest nonprofit funder of blood cancer research. We have funded more than $2 billion since our founding across all our different programs. Just today, we have over 330 active projects spanning 43 different blood cancers. Obviously, immunotherapy is very key. We have 90 different projects in immunotherapy alone. We have several different grant programs focused on bringing trials into community settings. And we have 17 active Therapy Acceleration Program partnerships. I will speak about this a little bit later. Annually, we receive more than 600 grant applications a year and review them through a multi-step peer review process. With blood cancer experts. So this is really the portfolio behind the myelodysplastic syndromes work that I will come to a bit later. Uh, next slide please. So shown here, this is how our research programs really map onto the development path. Starting from just an idea through basic research, preclinical drug discovery, and ultimately clinical research and all the way up towards FDA approvals. We have career development programs that are awards that support the most promising emerging scientists in blood cancers. We have some discovery grants that fund the earliest science. And then we have a couple of grant programs, translational research and specialized centers of research. These help discoveries move a little bit closer to clinical application. Then we have a couple of programs focused on trials. Academic clinical trial programs and impact programs support trials and access to community centers. Specifically today, I would like to focus on our Therapy Acceleration Program. This is where we invest and work directly with biotech companies such as Faron Pharmaceuticals. These are typically focused on clinical-stage assets, and the organization also has several master clinical trials, one called AML. They are celebrating their 10th year, actually, and the PedAL trial, which is focused on pediatric leukemias. These are master trials where we are actually the sponsor of the trial. We hold the IND, we run the trials with CROs and have dedicated sites committed to these diseases, especially in AML and for pediatric clinical development, respectively. We also run several special initiatives where there is a high unmet medical need. These include CML, hairy cell leukemia, mantle cell lymphoma, and follicular lymphoma. And these are typically co-funded or supported by a specific donor or another disease foundation we work in collaboration with. So for scale, our academic grant programs run approximately $40 to $50 million a year. And over the history of our organization, we have supported more than 4,000 projects in more than 80 institutions worldwide. So let me show you what that looks like at this current time in one specific disease. Myelodysplastic syndromes. Next slide please. So this is what our myelodysplastic syndromes commitment actually looks like across the whole organization. In biomedical research, we have 28 active myelodysplastic syndromes relevant awards for the Therapy Acceleration Program, where we focus on partnering with companies and investing. We have investments in four programs across three companies. One of them is Faron Pharmaceuticals and others are Onconova and Crossbow. Alongside these, we have three specialized centers of research. These are large multi-institutional grants. A $5 million commitment includes multiple principal investigators who are working towards one overarching goal. And obviously these are focused on the area of myelodysplastic syndromes. We have 14 career development awards in the MDS space, along with three discovery grants and two academic clinical trials. These are specifically funding investigator-initiated trials for using company drugs or drugs developed by the academic institutions running investigator-initiated trials and two impact access programs in the myelodysplastic syndromes space. So, obviously there are many different examples of what these programs are studying, but a few examples include RNA splicing, epigenetics—especially important in Myelodysplastic syndromes—TP53 mutant disease, clonal hematopoiesis, and other metabolic vulnerabilities. The message here really is that we cover everything from the bench to the bedside, even to patient access. And really, no single company or foundation can cover that span like we do. And this is what we bring to a partnership with any of our collaborators. One thing I did want to point out, as it was just recently announced, is that we have a collaboration with the Evans Foundation. They focus on myelodysplastic syndromes. They have a program called Evans MDS, and they have a policy commitment to do more collaborative myelodysplastic syndromes research. So we just announced that the Evans Foundation and Blood Cancer United are going to be supporting a new SCORE grant to bring together integrative, interdisciplinary teams from around the world to focus on MDS translational research, trying to bring more discoveries to the clinic. This application window is now open, and we hope to fund a new Myelodysplastic syndromes-focused specialized center of research (SCOR) grant next year. So now, as I transition to discussing the Therapy Acceleration Program, this is the part of the organization that works directly with companies. So let me now turn to that model and how it operates. Next slide please. So I know there is a lot here on the slide, but I will walk you through it. The Therapy Acceleration Program is our venture philanthropy program. And we've been supporting companies developing novel blood cancer therapies since 2007. So we are approaching our 20th year next year. So the different sections. So, first, I want to bring your attention to the circular bullseye on the right. This is a snapshot of all the biotech companies the Therapy Acceleration Program has ever supported. There are over 50 of them represented there. Some of them might be on the slide more than once because they might have different assets in blood cancers. They either show the current stage of development or where the program ultimately ended. The outer ring represents preclinical stage companies. As we move toward the center, you see Phase 1, Phase 2, and Phase 3, and ultimately FDA-approved therapies, of which several have been completed with Therapy Acceleration Program supported therapies. The blue boxes highlight recent or incremental investments over the last couple of years. And we have a couple other partners that are actually still in active development in blood cancers. So the main goal here is our mission. We invest to accelerate therapies to help cure blood cancers and improve patient outcomes. As I mentioned, in the center of the bullseye are six approved therapies that have either been FDA approved or included in the NCCN guidelines. These include diseases such as AML, lymphoma, and rare blood cancers called BPDCN and T-cell lymphomas. One of our most recent examples of approval for Therapy Acceleration Program contribution was a new class of therapies called MET inhibitors, which were approved last November. So when the Therapy Acceleration Program makes an investment, we invest as part of a syndicate with other like-minded investors. We take an equity position in the company. So the model is really designed to both impact our mission of accelerating the development of therapies and also provide a possible financial return. We have invested more than $120 million to date in these 50-plus companies. There are more than 30 active clinical trials running across the portfolio with Therapy Acceleration Program-supported therapies. Strategic transactions, financings, and financial returns do matter because these returns that come back to us can be recycled into the mission and help fuel the next generation of Therapy Acceleration Program investments. So over the years, we've been doing this for quite some time. We have built up a pattern recognition to distinguish companies that best fit our thesis for investments and have the potential to impact patient care, which is our primary driver. The next slide shows this thesis and what we look for before deciding to partner with and invest in a company. Next slide please. So these criteria are what we look for in a company during due diligence. And the same ones we have applied to Faron Pharmaceuticals, first and always first. We really look for the unmet medical need. What are the existing and emerging patient populations where patients have very few good options? Is there a real gap in the current and emerging treatment landscape? We look for innovative science, things that are first in class. If other companies and pharma are well covering a development target or particular diseases, we may be less likely to invest there. We can use our dollars to invest in a space where there is really that unmet need and a lack of standard of care. We look for whether there is a plausible path forward, either through a first-in-human study or even through registration-enabling studies, making sure that the company's plan is in alignment with the FDA and how we can assist them to ensure they have the best chance for success. In addition, beyond the science, we look into the company to ensure that it has the proper intellectual property. The management team is in place. They have expertise. They want to work well with us, and they have the ability to finance and execute the development plan. And it's an important framing point when we look at these opportunities. We are just looking for ones that fit these criteria. We have a due diligence process shown here. We typically look at over 100 inquiries a year. We are not really ranking these opportunities. We are looking for all the different companies that fit. If we have the capital to make an investment, we will. We are looking through a mission lens first, not looking for the best winners, but looking to see which companies can have the best impact for patients. So we have a very strict due diligence process. We have a number of staff members with expertise who conduct our initial due diligence. Ultimately, we work with some KOLs to provide additional feedback, and we have an oversight committee called the Therapy Acceleration Program (TAP) Committee, which reviews all of our opportunities. We want to make an investment. They oversee our program, and they have to give the go-ahead if we are to proceed with an investment. A lot of these national board members have investing, finance, and scientific expertise. Some of them have been former CEOs. Some are investors in other VC groups, so they have a lot of expertise and also help us perform due diligence on these investment opportunities. But it is very rigorous. We have been told that we sometimes perform much more rigorous due diligence on the science and management than other investors. So a lot of companies, if they make it through our due diligence process and become a partner, they really look at us for a seal of approval and can use it as a catalyst for additional financing. And really, we only make a few investments a year, typically bringing on 1 to 2 new partners. We are also reinvesting or following on with some of our current portfolio partners. As I showed you, this funnel shows a broad set of inquiries down to small investments. We look through investment inquiries year-round. And once a company is selected for investment, that is part of their syndicated financing. That is really where our true partnership begins. I will speak about that more in a little bit. Next slide. So this is our current portfolio of companies that we've invested in across the blood cancers. It really illustrates the breadth of the different partnerships. We certainly have a concentration in myeloid diseases, particularly AML and MDS, which obviously have a lot of high unmet medical need. Boxed in red is our current MDS portfolio for the Therapy Acceleration Program, which includes Faron Pharmaceuticals, Orano, and the two Crossbow programs. What I want you to see is not just different company logos, but it's really a living pipeline. We are always hoping when we join a company investment, whether it is preclinical or in phase one or phase two, we want to see them moving toward the right into pivotal trials and ultimately to approval. There is a whole host of different modalities. Stages of development. We are really agnostic to those. We have cell and immune therapies, targeted small molecules, antibodies and other approaches all selected because they address difficult blood cancer settings where better options are needed for patients. So, the concentration is not accidental. It really follows leading with unmet need. So this sort of gives you the portfolio view. But the next slide I am going to show you is looking at our commitment through a different type of lens. We have invested many dollars in the particular disease areas. Next slide please. So, putting the portfolio into context, we have committed our resources across all the different blood cancers. This chart shows our historical commitment over time, which, as I mentioned, is over $120 million. Looking at five-year survival for many of the large buckets of blood cancers and their annual incidence, which is represented by the size of the bubble. It shows how unmet need really aligns with where we put our substantial commitments in diseases where survival is the poorest. Shown here, those areas are AML, MDS and aggressive non-Hodgkin's lymphoma. This is just provided for context. It is not really a formula. We are not saying you can only invest in these areas, but this is how it has played out over time where we have made all our historical investments. So, really focusing on myelodysplastic syndromes, we've invested nearly $20 million in myelodysplastic syndromes alone across several different companies, including Faron Pharmaceuticals. And really behind those commitments are patients that have very limited options. And so, let me now reframe the unmet need in myelodysplastic syndromes before we can get to talking about our Faron Pharmaceuticals partnership. Next slide. So earlier on today's program, Amer Zeidan covered the clinical science of MDS in much greater depth. From the perspective of physicians who actually treat these patients, my role here is a little bit different. I just want to explain from our perspective why high-risk MDS is such an unmet need. It is urgent and it is patient-centric. That drives our commitment to making these types of investment decisions in these blood cancers. High-risk MDS is a disease of older adults. Many are too frail for intensive therapies or transplant. The standard of care is HMAs, which produce overall response rates of roughly 40-50%, but only 10 to 16% receive complete responses, and many of those are transient. The harder numbers are really compelling. What happens after you fail the initial therapy? Once they stop working, there is really no proven therapy and overall survival is only several months. So for most patients, after they fail, the next conversation is supportive care. Not really. What is the next therapy they can pursue? Underneath these survival statistics are the daily lives of patients. Patients have to deal with cytopenias, transfusions, infections, and frequent trips back to the clinic. It is really about quality of life in addition to being a survival story. Also, there are some adverse molecular subgroups. Myelodysplastic syndromes. Right. We've talked about before TP53-altered disease; these patients fare worst of all. So having therapies that can address these patients is critical. So that is really the gap we are looking to address. When we evaluated Faron Pharmaceuticals, before I walk through the partnership timeline, let me first explain how the program fits our mission and development lens. Next slide please. This slide highlights five reasons why the Faron Pharmaceuticals program fits our mission lens. First, unmet need. As I mentioned, that is the first thing we look for: substantial unmet need in both frontline and higher-risk failure. Myelodysplastic syndromes: second, there is great science, as Bexmarilimab targets Clever-1, a novel target with unique biology. There is a distinct mechanism involved, especially including an azacitidine-based regimen in combination. Third, there is clinical data. There are clinical signals from the BEXMAB trial, including some response observations in TP53-altered disease. And as we go through the partnership, this has informed us to make several different funding reviews. We have continued to be encouraged by the development and have made three investments in Faron Pharmaceuticals so far. Fourth, the development path now includes a randomized follow-up study to really test these early signals. This is always critical as you move forward to determine if it has a chance to get toward approvals and to see if there is meaningful patient benefit. And five, we look for companies where we see a role for our organization. The Therapy Acceleration Program helps companies through disease insight, providing our patient perspective, getting expert inputs from some of our KOLs, and helping with development networks. These are the five areas that we thought Faron fit, and I am happy to go through the partnership in a second with you, Juho. To be clear, Bexmarilimab remains investigational, and randomized studies need to be conducted to establish additional patient benefit. So really, let's now go through the partnership to describe and show everyone how it has developed over time through several different reviews and our staged investment process. So, I would like to have you join me for the next couple of slides.

Juho Jalkanen
68:59 - 69:55

Thanks for having me, Blaine. Happy to be here with you and discuss the partnership. So, next slide, please. Yeah. So we thought it would be also good for the audience to really understand how we've been working together and how our partnership has evolved. So it actually all began in 2022, when we were wrapping up our first in-human trial with bexmarilimab in solid tumors. The most important learning from the first in-human trial was that patients who had Clever-1 positive macrophages in the tumor microenvironment benefited. So we screened a lot of databases, and we learned that AML and myelodysplastic syndromes are basically all Clever-1 positive. And that is an area we need to move into. However, we lacked the expertise to do so. We had limited experience in the heme space. So that's when we reached out for the first time to Blood Cancer United and started the dialogue.

Blaine Robinson
69:56 - 70:45

Yeah, exactly. You know, it is interesting. So that's when we made our first investment in June of 2022. I actually looked back this morning and found that we first connected at a J.P. Morgan conference in January of 2021, during COVID. We worked and engaged with Faron Pharmaceuticals over 18 months, looking at a strategy, the data, connecting with experts, and ultimately, given all that preclinical data and rationale, as you mentioned, especially moving into AML and MDS, we made an initial $500,000 investment and took Faron Pharmaceuticals through the entire stage diligence process. This is one of our few investments made coming out of Covid when dollars were limited. That investment helped support the expansion of the existing MATINS trial, moving into AML and high-risk MDS, and helped support clinical protocol development.

Juho Jalkanen
70:47 - 71:18

Yeah. And ultimately, that initial investment resulted in the BEXMAB protocol, and early on in the Phase 1 dose escalation, we saw very strong signals and large reductions in relapsed/refractory patients where you usually do not see any response. We were seeing this and again, we sat together and decided we needed to move on to the phase two part. And we needed further investment. So that brings us to 2023 then.

Blaine Robinson
71:20 - 72:03

Yeah, exactly. When we made the initial investment in June, obviously we were collaborating together. We were following the data. I have to say, from being in the organization for quite some time, making a subsequent investment is something we have done several times, but doing it within seven months was notable. That sort of goes to show that the company was able to execute and all those early signs are really promising. So we took the company through our due diligence process again, and Faron Pharmaceuticals had to present in front of our Therapy Acceleration Program committee to get approval. And we ultimately agreed to do a larger investment, this time another $3 million, to help support part of the BEXMAB study and also to start enabling expansion into the US sites, where we think the Therapy Acceleration Program could be helpful given our network and experience.

Juho Jalkanen
72:04 - 72:26

It was very essential because that way we were able to expand to the US, get more sites, get things moving for the Phase 2 part and execute on the Phase 2 part. And ultimately, the Phase 2 then confirmed those early signals seen in Phase 1, which then led to a successful end-of-Phase 2 meeting with the FDA in the fall of 2025.

Blaine Robinson
72:28 - 73:29

Exactly. We were following all along and were very excited to hear about the engagement with the FDA and the plans to move forward. And based on that meeting, we again brought our portfolio companies to the Therapy Acceleration Program committee to give them updates on how things are going, as we believe things are going really well. They are engaging, and they are developing a plan to move forward. We were discussing the registration study. So both our Therapy Acceleration Program team and the committee expressed continued support for another investment in the near future. We would continue to follow the data and development plans. We knew the company was preparing to present some data at ASH. So we are looking forward to getting those updates and hearing more about their plan. And then, after those checkpoints happened, the ASH data came out, and the company came up with a financing plan. They revised the plan. So we brought the opportunity back to the committee. The committee was supportive again. And we made a third investment of €3 million as part of financing at that period to finance the randomized BEXERA trial.

Juho Jalkanen
73:30 - 73:46

Exactly. So this is how I see what we're looking at in this slide and in this four-year period, Faron emerged as the leading company in higher-risk myelodysplastic syndromes. Or how would you summarize this?

Blaine Robinson
73:48 - 74:20

Yeah, it has really been a wonderful partnership as the years have progressed; it really reflects the continuity over these different columns showing here four years of collaboration, successive reviews of encouraging data, the development plan moving forward, and execution. This has led to different investments. And really every milestone along the way has given us the opportunity to evaluate the science. How is the Faron Pharmaceuticals team executing the plan? What is the path forward? It is never really about a single check. It is really about the relationship with the company. And it deepened as the data matured.

Juho Jalkanen
74:22 - 74:44

Yes. So we thought it would also be beneficial to talk a little bit about what this actually means in practice. So how do you work not just with Faron Pharmaceuticals? This is not just about Faron Pharmaceuticals. It is the amazing work that is being done in general. So how do you work with companies actually in practice? And again, it is with us but also with other companies. So could you explain?

Blaine Robinson
74:45 - 75:46

Exactly, this is a really important piece; we are not just giving out dollars and checks and waiting to see what happens. We want to work and find companies that want to collaborate with us, and we really think that our organization and the Therapy Acceleration Program brings a more partnership and a value-add beyond just the dollars. It is really about the continuing collaboration with whomever the biotech partner is. This is where our value proposition really becomes a little bit more concrete for every partnership. We form a research advisory committee. And so we form it between our Therapy Acceleration Program team and the company team; in this case, obviously Faron Pharmaceuticals, it is done when we make our first investment, and it is really structured. That is put in place so that we can have recurring dialogue all throughout the year, typically quarterly, both virtually and in person as possible at some of the scientific meetings, really to touch base to make sure we're assisting the company however we can. Every company is a little bit different. Some need more expertise on the science side, clinical connections, others might need more business development support.

Juho Jalkanen
75:48 - 76:18

Absolutely. And I think one of the key things that really differentiates or sets Blood Cancer United and the Therapy Acceleration Program apart from anything else that I've seen is actually your engagement and network of leading KOLs and sites. So you can really tap into the best minds of the field. And then companies can benefit from that through you. So I think that is the real key to how you differentiate yourself and your uniqueness.

Blaine Robinson
76:19 - 78:21

Exactly. I mean, as I mentioned, we engage KOLs in several different ways. We utilize some during our review process, as we do with every company. Some of the KOLs may be more expert in the target area or the particular disease or development plan, but once we become partners with companies, we can help convene the right clinical voices around trial design, endpoints, selecting patients, and those types of things. We have organized events at ASH, bringing in KOLs to meet with companies. We have made specific introductions to companies, saying, hey, you know this. And hearing from us is an easier connection than a company just trying to reach out to some expert they want to connect with, right? If it comes from us, we can say, hey, we know this company. They are doing really great things. They had some presentation at ASH. Maybe we were not able to see it. What do you think about it? And all the time the KOLs are like, "Hey, this looks really great." Put me in contact with the company. And you know, maybe they become a site, maybe they become an advisor, or maybe just someone they can sort of bounce some ideas off of. So it's really been a wonderful collaborative aspect that we bring to all of our partnerships. And not only KOLs, we have other resources within our organization like Blood Cancer United. We have a clinical trial support center, for example, where we have almost 20 nurse navigators. They speak directly with patients and caregivers. They are always looking for what trials patients are eligible for? You know, are there slots open and access? How do they get access to these sites? Are there any barriers to enrollment? We always encourage our Therapy Acceleration Program partner companies to speak with the nurses, give them the most updated information about the trials, and explain what is happening so that, obviously, the job of the clinical trial support centers is to help more patients access clinical trials, because we all know these are often much more beneficial than just receiving the standard of care. So it's really the patient-facing perspective that we can bring for companies helping refine their clinical development plans, enrollment strategies, and obviously, moving forward with companies that are getting closer to the finish line, discussing the registration strategies becomes a really great discussion point between us and the Therapy Acceleration Program partners.

Juho Jalkanen
78:22 - 79:05

Absolutely. So maybe just to sum up what I see here, and again, it is one of the specialties of Blood Cancer United and the Therapy Acceleration Program. So there's this very operational side. We're working together even on a site scale level, meeting frequently on an operational level. But then there is the Therapy Acceleration Program committee that ultimately makes the investment decisions through a continuous operational partnership. We have then repeatedly gone back to the Therapy Acceleration Program committee, keeping them up to date on the evidence as the development plan builds up, which has ultimately led to this. I would say it is an amazing and very flourishing partnership.

Blaine Robinson
79:07 - 79:54

Yeah, exactly. I mean, we make the investment, but our role really is to help collaborate, advise and convene whatever the companies need. In this case, the company Faron Pharmaceuticals owns the program and makes their own decisions. We are just the advisors. We are not taking board seats and those types of things. That is how we do this: through our collaborative research advisory committee model, trying to make those connections and even beyond, we have made connections with companies on the business side, introducing them to other investors. Our organization works with many of the large pharma companies. We can try to make introductions and those types of things. So, we kind of bring a full engine to all these partnerships to try to obviously bring the science forward and impact patient lives as best we can.

Juho Jalkanen
79:55 - 80:00

Wonderful. So a true partnership, if I may add, in its truest sense.

Blaine Robinson
80:00 - 80:24

Exactly. Yeah, exactly. That is what I always like to talk about. You know, our Therapy Acceleration Program partners, we always say Therapy Acceleration Program partners. It's a partnership. If there is a company that wants to take our money but does not really want to work with us, this does not really work for our model, right? We really want to be very collaborative and true partners. So, we are contributing alongside our investment, which is a unique angle on how venture philanthropy should work and how we operate.

Juho Jalkanen
80:25 - 80:37

Thanks a lot, Blaine. Let's move on to the next and last slide, and you can wrap it up. Amazing work. We want to raise awareness of this work that Blood Cancer United is doing. Over to you, Blaine, to wrap it up.

Blaine Robinson
80:39 - 82:26

Thank you. Yes. First, thank you for the opportunity today. So just a couple. Take-home points from today. Blood Cancer United, our organization, really exists for patients to cure blood cancers and improve the quality of life for patients and their families. Our venture philanthropy program, Therapy Acceleration Program, can help accelerate mission-aligned innovation, providing capital plus expertise and collaboration from a patient-centered perspective. Third, high-risk myelodysplastic syndromes. It remains a major unmet need. New therapies are needed for patients, specifically more tolerable and effective therapies that must be tested in rigorous studies. Fourth, Faron Pharmaceuticals is a current Therapy Acceleration Program partner, as this program aligns with the HR-MDS unmet need and has unique biology and a unique mechanistic rationale. It has clinical data so far that has been very encouraging. And a promising clinical development path moving forward. It fits all the checklists. If you take one thing away, our commitment to myelodysplastic syndromes runs from early science at the bench to bedside and patient access, and Faron Pharmaceuticals fits all those boxes and sits inside of all that has been shown here today. I really wanted to acknowledge some of our supporters as we have been looking for support to help financially provide dollars to the Therapy Acceleration Program to make additional investments and to grow our program. So I want to acknowledge a recent partnership with Royalty Pharma, and a couple of foundations, the Butler Family Foundation, and also Blood Cancer UK. They are all our supporters now. They are helping to expand our reach and impact, fueling our growth and trying for our Therapy Acceleration Program to become a self-sustaining venture philanthropy. So really, the goal is simple: to help move promising science to patients who urgently need better therapies. So thank you very much for the opportunity to present today.

Juho Jalkanen
82:27 - 82:37

Thank you. Awesome work. Just checking for any questions from the audience for Blaine, or shall we let Blaine go?

Unknown 1
82:40 - 82:53

Yes, there are a few questions for Blaine. There is a lot of discussion about that. How do you view the data overall, and how would you describe the data that we have seen? How promising is the data that we have seen so far?

Blaine Robinson
82:54 - 83:08

I am not going to speak about the data today. I mean, obviously, I think from my perspective, the Therapy Acceleration Program has made several investments in the company. So I think that surely suggests that we are encouraged by the data and looking forward to the registration study starting.

Unknown 1
83:09 - 83:26

Thank you. And there is a second question about the Therapy Acceleration Program (TAP) philosophy: do you support a broad range of programs, hoping to find one that will make the change, or are you very selective with these investments and do you need a high level of conviction?

Blaine Robinson
83:29 - 84:00

So I think if I understand the question right, when we make investments, we are very selective in programs. They have to check off a lot of boxes, as I discussed before. We are looking for high conviction programs for us to make a subsequent investment in the company. We are not like another investor that would just keep pouring dollars into a company just to maintain our shares and our levels on the cap table. We only make investments in companies where we feel there is forward momentum in blood cancers to justify an additional investment.

Unknown 1
84:01 - 84:03

Thank you. That was the last question. Over to you.

Juho Jalkanen
84:04 - 84:59

Okay. Thank you. Proceeding. We are on time. So wishing you a wonderful day. And then I think we are up to the break. We will now align our timetable with another external expert coming soon. We will now have a 20-minute break. So we are continuing until the 16:45 finish time. 15:45 Central European Time. Thank you and see you soon. Welcome back, everybody. I hope you had a good break. A fresh cup of coffee. Now, next is what else is happening at Faron Pharmaceuticals. And here to tell us all about it is our Chief Medical Officer, Petri Bono, on the pipeline review and other ongoing trials. Over to you, Petri. Thank you and good afternoon, everyone.

Petri Bono
84:59 - 106:36

And good morning to us. I am really delighted to tell you about our pipeline review. Let's start with the first slide. We have made very good progress recently. And this is the current pipeline. And you can see there the second trial is BEXMAB, where we already a year ago stopped enrollment of new patients. It is important to remember that although the enrollment is closed. So the study data continues to mature. We released the newest OS data to the market in July. And in an upcoming major hematological meeting, we will present the newest data in more detail. Then Amer Zeidan presented the design of the BEXERA trial that is in the treatment-naive, higher-risk MDS patient population. We are on track. We have previously informed the market of our progress. The study will start enrolling patients in Q4 this year, and we are on track with that. And very excitingly, we have Blaze and BEXERA that are no longer just in planning. Both are up and running. Both have received all regulatory approvals, and we have actually informed the market that the first patients have already been enrolled in both BEXERA and the BLAZE trial. It is a metastatic soft tissue sarcoma, and we will hear today more in detail about it from the study principal investigator, Doctor César Serrano from Barcelona. Then I will update the BLAZE situation and BLAZE design. Blaze is a trial where we try to overcome secondary resistance to PD-1 inhibitors in metastatic melanoma and non-small cell lung cancer patients. I am proud to share that today we received information that the first cohort in BEXERA is fully enrolled, and the second cohort is now open for enrollment. In the BLAZE trial, we have already treated two patients who have started their therapy, one at The Royal Marsden Hospital in London and the other at The Christie Hospital in Manchester. So both trials are in solid tumors. These are investigator-initiated trials. They are also progressing very nicely. As mentioned. So Blaze and BEXERA are no longer just at the first patient in stage, but are now up and running. And of course, since they have had such a good and strong start. So it means that we can expect to have results from this trial in H1 2027 next year from the first part of the trial or first stage. And then we have also another two IIT trials that are progressing. Also the preparations. The other one is the Nordic AML trial. The BEXMAB trial is led by Doctor Mika Konttinen from the Helsinki University Hospital together with the Karolinska Institute. So it's Bexmarilimab plus Azacitidine in MRD-positive AML patients after transplant. And that trial is currently at the submission stage. And then the other trial is an investigator-initiated trial run in California at the City of Hope Comprehensive Cancer Center that is in relapsed and resistant MDS patients. Combining bexmarilimab for the first time with an oral agent, in this instance, it is Inqovi. That is a combination of Decitabine plus Cedazuridine and these are patients with progressing disease. We are finalizing the full protocol with the City of Hope trial and then the other one, BEXMAB. So it is to be submitted extremely soon. Then a couple of words. What is the rationale actually behind this? It's time to go a little bit more in depth into that. So let's start. What we have learned from the MATINS trial. And as a reminder, Matins was a single-agent Bexmarilimab treatment for patients with advanced metastatic solid tumors. At that time when MATINS was started, I was working still at the Helsinki University Hospital Comprehensive Cancer Center and had the privilege to be the global PI of the MATINS trial. Altogether, 216 patients were enrolled in the trial from various large European cancer centers. We gained many valuable insights from the trial. First of all, it is good to remember that patients were really late-stage patients. They had received a median number of previous treatment lines of three before entering the trial. So it wasn't a frontline metastatic trial at all. And why this is important when we're talking about a novel immuno-oncology agent. You also need to have a good immune system so that the immune system is not too exhausted to get the benefit from IO treatment. And in. So in that way, MATINS wasn't the optimal setting. But this is always how it goes with first-in-human trials, as late-stage cancer patients are enrolled. So what we were able to show in the MATINS patients is that we were inducing macrophage activation that led to treatment benefit in solid tumor patients. And this is really important. The clinical benefit we observed in some cohorts was in 25 to 35% of the patients, including liver, gastric, and melanoma patients that were benefiting from the treatment. We also learned that targeting Clever-1 with bexmarilimab is extremely well tolerated. The rate of adverse events was low. Immunological adverse events were extremely low, and the rate of any treatment-emergent adverse event was also not high, including treatment-related adverse events. Treatment-emergent adverse events were not high, and treatment-related adverse events were as well. We only had less than 10%. Grade 3 or higher treatment-related adverse events. Then, we were able to show that it is realistic to achieve disease control in late-stage cancer patients with single-agent Bexmarilimab treatment. And very importantly, we were able to show that low baseline immune activation is associated with Bexmarilimab treatment benefit, and this is important. Those patients who have low baseline immune activation status are typically patients who do not respond to PD-1 inhibitors. And also, we were able to show in the translational studies that bexmarilimab converts intratumoral macrophages to support adaptive immune responses. Also, based on the translational results, we were able to show that we have a good biomarker candidate. That is the intratumoral Clever-1 positivity by immunohistochemical staining. When we talk about checkpoint inhibitors within solid tumor patient treatments, it is important to remember that although there has been a lot of activity over the last ten years, they have transformed the treatment of cancer. So actually, just 20% of the patients do respond to checkpoint inhibitors on the right side of the slide. This is from a Lancet review. You can see the reasons for the mechanisms of resistance. So there are several mechanisms. Actually, many of these are related to macrophage function. And then on the left side, we can see how many patients actually respond to checkpoint inhibitors? You can see that, for example, in Hodgkin's lymphoma and melanoma, 50% or more of patients benefit from PD-1 inhibitors. But on the lower side of the left-side figure, you can see that these big tumor types like liver cancer, colorectal cancer, and hormone receptor-positive breast cancer actually have less than 15% of patients who get benefit from PD-1 inhibitors. So from the patient's perspective, there is really a lot of need for further improvement of the treatments. And what do we know about Clever-1 mRNA expression and its association with the survival of patients from large databases? On the left side, you can see the Kaplan-Meier survival curve that shows Clever-1 or the mRNA coding for STAB1. So the expression level is associated with patient survival. It is associated among all cancer patients with a worse prognosis. The high Clever-1 patients are shown in red. So their Kaplan-Meier curves are clearly inferior to the blue ones who are Clever-1 low. And on the second panel from the left, you can see separated immuno-oncology therapy treated patients. And the difference is even higher there, so that the ones who are Clever-1 high. So they are actually the ones with the worst prognosis. And then on the right side, we have also done a split between the IO treatment between PD-1 inhibition and between CTLA-4 blocking. And the same result holds true there. And then I would like to spend a little time with this slide that is taken from a very elegant Chinese paper that was published last year in the Journal of ImmunoTherapy of Cancer. And this is one of the good reasons why we want to study it in solid tumor clinical trials. The combination of bexmarilimab, for example, with PD-1 inhibitors. Maija has shown earlier mouse tumor work that also supports that. But this is an external validation from gastric cancer patients and gastric cancer data showing that Clever-1 expression is actually related to clinical resistance to nivolumab. It is related to CD8+ T cell functioning and also related to tumor cell killing. On the left side, the patient numbers in that paper were still fairly small, but for patients who were treated with the combination of 5-FU, oxaliplatin, and nivolumab—gastric cancer patients—not all patients achieved a response. And when the tumor-associated macrophage infiltration was analyzed. So the responders are in blue versus the non-responders in orange. So they had a much higher Clever-1 positive rate than the responders, indicating that Clever-1 expression is really related to the treatment resistance to a PD-1 inhibitor. In the middle graph, they isolated tumor cells from gastric cancer tumors, placed them in a petri dish, and treated those cells with either a control antibody, nivolumab, a PD-1 antibody, an anti-CTLA-4 antibody, or the combination. As you can see in purple, the combination. So the dual blockade. It produces the strongest interferon-gamma response in these tumor-infiltrating CD8-positive T cells. This is a very strong rationale to move to the clinic and treat patients with the combination of interest. So, as a single agent, anti-Clever-1 antibody was at least as efficient as nivolumab. Or even a little bit better. The same direction or trend can be seen on the right panel as well. This was not measuring T cell reprogramming. The right panel is measuring apoptosis. So, tumor cell killing and how that is enhanced. It is best in Clever-1 positive tumor microenvironments with high tumor burden when using the combination. In summary, this elegant Chinese work. This. It makes a really good rationale to move forward also with the patients. So then, where are we actually? And how do the IITs look? Blaine. BEXMAB is a melanoma and non-small cell lung cancer study. This is a lung cancer study in second-line treatment after the patients have failed their frontline checkpoint inhibitor or PD-1 inhibitor therapy. It is testing whether the addition of Bexmarilimab can overcome the secondary resistance of these patients in order for patients to be enrolled in the trial. They need to have received a PD-1 inhibitor. They need to have received a response to that. And then before entering, they need to have received the latest PD-1 treatment within three months. This is a phase 1/2 investigator-initiated study where part one will include approximately 10 to 12 patients, and part two will then include 25 melanoma patients and 25 non-small cell lung cancer patients. The primary objective is safety and overall response rate in this trial with the rechallenge of the PD-1 inhibitor. For example, in melanoma, you do not expect more than a 5% response rate there. So within the first ten patients, even one response would mean a green light to proceed to the phase two part of the trial. Then BEXERA, this one I will do very shortly since César will go through it. I just want to highlight that by purpose. This is in frontline patients and in frontline. Because the immune system of the patient is optimal to be treated with Bexmarilimab. And this trial is a combined phase 1b/2 trial. The first Phase 1b/2 trial will include up to 46 patients with PFS and safety as primary endpoints. And then the City of Hope trial, which is extending Bexmarilimab evidence to an oral hypomethylating agent backbone. The rationale, of course, from BEXMAB, we know that combining Bexmarilimab with Azacitidine. It has really encouraging efficacy, but at the same time, we know that oral use of HMAs will be increasing. And with Bexmarilimab, of course, we will need evidence that its activity can be translated from IV or subcutaneous Azacitidine also to oral agents such as Decitabine, Cedazuridine or Inqovi, which is the brand name. This trial is planned to include 34 patients. It is an open-label, Phase 2 investigator-initiated trial that will be run in the network of City of Hope. They have satellites elsewhere also in the US. Sorry, elsewhere in the US, in a couple of major cities. The primary objective of this trial is to measure the OS rate at 12 months and also the overall response rate. And as we know, when patients fail a frontline treatment. So basically, you don't get any responses, or it is again less than 5% of the responses, and the overall survival rate at 12 months. So, we typically talk about 25%. The plan is to increase that from 25% to 50%. And then BEXMAB. So BEXMAB is a setting where we have a low disease burden that will allow bexmarilimab-driven immune and hematological effects to be detected before an overt disease relapse, so that post-transplant AML patients, when they become MRD positive with sensitive measures, will receive azacitidine plus bexmarilimab in an open-label Phase 2 investigator-initiated trial. Planned trial size is 24 patients, and the primary objective is MRD negativity at 24 weeks. And this was my last slide about the pipeline and the activities related with these trials. I am really proud of the progress we have been making over the last couple of months with these trials. And my purpose is not to touch too much today on the BEXERA trial, since that will be presented by the next presenter, Dr. César Serrano, who is a group leader of the Sarcoma Translational Research Program at the prestigious Vall d’Hebron Institute of Oncology in Barcelona. César is also a valued faculty member. Also this year at ESMO, in two weeks, he is leading sessions there as a moderator. He has been long involved with both translational and clinical research of sarcoma treatments and certainly represents a true key opinion leader within Europe in this disease type. So without further introduction, César, please. The stage is yours.

César Serrano
106:37 - 119:50

So thanks so much, Petri, for your very nice introduction. And hi everyone. Over the next few minutes, my idea is just to transmit to you why it is important to target Clever-1 in patients with sarcoma, and why I think this is a low-hanging fruit. So maybe you have heard this before. Clever-1 is a protein that is primarily and uniquely expressed in cells of the myeloid lineage under physiological conditions. Clever-1 has multiple functions that help the body. But the problem arises in the context of a tumor type where it actually promotes tumor growth, mostly through altered leukocyte trafficking and inhibiting T-cell activation, basically creating an immunosuppressive microenvironment, which as you may know already, is pro-tumorigenic. What is known quite well is that high Clever-1 expression in cancers is associated with poor prognosis, and it also contributes to tumor resistance. This is based on clinical studies making an association between the expression of the Clever-1 protein and the STAB1 gene. That is the same for Clever-1 and patient outcomes. Next, please. So the fundamental for working on STAB1 gene inhibition or Clever-1 protein inhibition in sarcoma is actually very rational. So what we did at some point was to study across all the tumors that have been profiled under the TCGA to check for the expression of the STAB1 gene that is responsible for Clever-1 protein expression. And we observed that among solid tumors, basically, sarcoma is the second. Together with mesothelioma, they are the two foremost, and with a big range of expression of the STAB1 gene, we established a very nice and interesting rationale for targeting STAB1 in sarcomas. It also aligns with observations from many papers published in the field in recent years. In recent years, basically the main immune infiltrate that we have in sarcomas are macrophages that promote a tumor microenvironment that is immunosuppressive. So it is quite well connected. This immunosuppressive microenvironment in sarcomas, with a predominance of macrophages, is well connected to this high STAB1 gene expression. Next. There are multiple sarcoma subtypes, which you will see in a minute. But these six that you can see here are basically the most common sarcoma subtypes, representing up to 80% of sarcomas. So we could observe in this same preliminary study of RNA expression of STAB1 that there are differences in this STAB1 expression across the different sarcoma subtypes. And basically the three on your right are those that express a higher quantity of the STAB1 gene. And basically, these three subtypes are the most common sarcoma subtypes that are typically treated by chemotherapy in our daily clinical routine. So these findings are actually foundational for what is going to come in the trial design that I will speak about to you in a minute. Next, please. So, what are sarcomas? Sarcomas are tumors of mesenchymal origin. There are nearly 70 sarcoma subtypes and 150 tumors of mesenchymal origin. And the big problem that we have with these patients is that the main treatment for localized disease is surgery, perhaps radiotherapy too. And then when this disease is metastatic, which occurs in more than half of the patients, we have been treating these patients the same way for the past three decades. Basically, doxorubicin and anthracyclines are the most typical agents that everyone is familiar with. The problem with doxorubicin is as follows. First, the activity is relatively modest, with an overall response rate of 10 to 15%, median progression-free survival of around 6 to 8 months, and the very last two clinical trials challenging doxorubicin as a single agent, which you can see in the table up on the right. Basically, they were negative for the endpoints, which transmits to us, first, that they weren't the right combinations, but it is feasible to do in the sarcoma community trials challenging doxorubicin first-line combinations. There is a wide array of sarcoma subtypes that can be treated with specific drugs for those subtypes. But we do not truly have a biomarker that can direct the use of these different TKIs or agents that you can see in the table. Bottom right linking those with subtypes. So we have significant challenges in treating these patients. And we have not improved outcomes of sarcoma patients for the past 2 or 3 decades. Next. Here is the mindset as to why targeting Clever-1 in sarcoma is such a low-hanging fruit. First, the rationale regarding Clever-1 that you have heard before is that it is the solid tumor with the highest expression among specific sarcoma subtypes that we know express higher STAB1 gene levels, and these are actually the most common subtypes; second, these patients have poor outcomes with drugs that have remained the same for decades and show very modest activity. Next. So, why combine chemotherapy with bexmarilimab? There have been few clinical trials. Two or three clinical trials combining chemotherapy with checkpoint inhibitors have shown very limited efficacy in soft tissue. Soft tissue sarcoma, basically, because as you have seen before, the microenvironment is already quite immunosuppressive for PD-1 inhibitors as monotherapy or in combination to help produce any type of effect. Also, we know that chemotherapy can prime tumors for immune responses and upregulates Clever-1 expression. You'll see that in a minute. So, there is a strong biological rationale that combining cytotoxic chemotherapies with immunotherapies may offer a maximization of the therapeutic response and improved patient outcomes in the short term. Next. So some data that I wanted to share with you regarding some of these affirmations. I just made it. So first is that Clever-1 blockade in combination with chemotherapy has broad potential, and sarcoma is one of the main paradigms. So we know that there have been many reports already that chemotherapy and many types of chemotherapy can actually increase the infiltration of STAB1 expressing macrophages, which actually leads to a more immunosuppressive tumor microenvironment. And there is also clinical data, as you can see in the upper part. First, that high STAB1 expression after neoadjuvant chemotherapy in ovarian cancer decreases patient outcomes. And in the lower part, you can see the Zhongshan cohort from Shanghai in China, which finds that actually, Clever-1 high expression in the tumor microenvironment infiltration is associated with poor outcomes regardless of the stage of the disease in gastric cancer. Next, we also have some data from in vivo studies performed in different types of mice. Basically, here you can see the feasibility of combining chemotherapy, in this case 5-FU, with bexmarilimab, and second, we can see the analysis of how the addition of bexmarilimab to the chemotherapy improves the tumor microenvironment and the infiltrate, making it less immunosuppressive. It was assessed on the left. You can see by flow cytometry in the blood, and then on the right, within these knockout mice. So we have this proof of how this first occurs in patients. The increase of a more immunosuppressive tumor infiltrate is mediated by macrophages expressing Clever-1. And second, that the combination of chemotherapy plus bexmarilimab is feasible. And then it rewires the tumor microenvironment. Next. So, altogether, the evidence in sarcomas about Clever-1 expression, the knowledge about chemotherapy inducing Clever-1 and this immune infiltrate based on Clever-1-expressing macrophages, and then the clinical unmet need that we have in sarcomas. And the feasibility to do these trials led to this Phase 1/Phase 2 trial that we currently have active in Spain. So here, we are studying the combination of first-line doxorubicin. So, doxorubicin with bexmarilimab. So we have first. This is what we have ongoing. Now the dose escalation is followed by a dose expansion. And then if this is positive by the endpoints that we've set, we will follow by a Phase 2 randomized clinical trial, basically in the dose escalation, for which we have now just opened the second cohort. So we said doxorubicin 75 mg/m². This is the standard dose. Why? Because as you've seen before by Petri and others, the tolerability of Bexmarilimab is wonderful actually. So it makes it easy to combine. And we established the dose as the standard one with increasing levels of Bex. So, the dose escalation is over. We will start with the expansion and later with the Phase 2 in this expansion. Basically, we will allow only the soft tissue sarcoma cases that were included in the TCGA. So we have a rationale about the potential expression of Clever-1 and the activity that these patients will have with a combination. We have a TAP design. So we will be able to have, despite relatively modest numbers, some very interesting data about the activity. So if this is positive, we will move to a randomized setting with basically the same design. These are six cycles of doxorubicin together with bexmarilimab followed by bexmarilimab alone. After doxorubicin is finished. And the endpoints are basically the typical ones regarding MTD, tolerability, and also efficacy for the phase two. Of course, it will be PFS. That is a very common endpoint and objective for sarcoma trials. Next. So this is the clinical trial. We are actually at the finishing line of June 2026 already. We have already included three patients in the trial in the first dose level, we cleared it, and now we are starting the second dose level with three slots available; investigators have already applied for those slots. So we are recruiting very rapidly and we aim to have initial results around April, May, of the next year, very rapid results. But this is actually what we want to move on in this trial, as we aim also to squeeze this time, but probably by the beginning of 2027, we will have the full data set that will be moved towards the phase two trial. So the timelines are being committed. The investigators here are very excited because there is such a strong rationale behind this clinical trial. We also think that we may finally have a compound that can challenge doxorubicin, the single-agent standard of care in sarcoma for three decades. So thanks so much and happy to take any questions.

Petri Bono
119:52 - 120:01

Thank you, sir. Fantastic progress. First cohort is already full, time to take some questions. Do we have any questions online?

Unknown 1
120:02 - 120:23

Thank you, Patrick. We have a few questions. After years of working in sarcoma research, what gives you confidence that targeting Clever-1 with bexmarilimab may succeed where many previous approaches have delivered only limited benefits? What gives you confidence?

César Serrano
120:25 - 121:14

So what provides that confidence? Thanks for the question. What gives me the most confidence is that soft tissue sarcomas are the solid tumors with the highest expression of the STAB1 gene. So there is a strong, sound biological rationale that we actually lacked in the past. Prior combinations with avelumab never had a biomarker there. Other chemotherapies never had biomarkers associated with them. Even PD-1 inhibitors in small trials. We never had a true biomarker there. So here we know that, especially some entities that are those sarcomas with complex genomes that are actually the most common, they do express high levels, very high levels of STAB1 gene. And this is what gives me the most confidence, the sound biological rationale behind it.

Unknown 1
121:15 - 121:27

Thank you. Next, what would be a clinically meaningful improvement over historical outcomes seen with chemotherapy alone that you would like to see in this combination treatment.

Petri Bono
121:28 - 121:44

May I add a little bit regarding the Phase 1b dose escalation and dose expansion part of the trial. Not the latter part, the randomized part, but what would you consider a very positive result in the Phase 1b part.

César Serrano
121:47 - 122:57

So there are two positive results. Okay. I am saying that because of the response rate. Okay. Sometimes we pay attention to response rate. That is quite low, 10-15%, with doxorubicin as a single agent. So something that we can even come close to doubling, like a 25% response rate, would be high. Just imagine that a 25% response rate is something we can achieve with the combination of doxorubicin and ifosfamide in some settings using two chemotherapies. So that would be a good result. But I am saying that we have a double expectation because of immunotherapy. What we know in the field is that there is an established long delay before the disease returns. Okay. So if we move from six to eight months of PFS to something like 12 months, one full year, that would be a significant improvement because these patients progress quite rapidly. And again, PFS is a very common surrogate marker for overall survival in sarcomas, widely accepted by regulatory authorities.

Unknown 1
123:00 - 123:03

Thank you sir. No further questions on this point.

Petri Bono
123:04 - 123:25

Okay. Thank you. Thank you so much. This was a brilliant presentation. Finally, one comment. So, we do have you will be presenting at ESMO, trials in progress, poster about the BEXERA trial. So really looking forward to seeing that and hope to see you in Madrid.

César Serrano
123:27 - 123:31

The same year. See you in Madrid soon. Soon. Bye-bye. Thanks so much.

Petri Bono
123:34 - 123:54

And next, we are going to move forward with our program. It is about the Bexmarilimab market opportunity. And Ralph Hughes, our Chief Business Officer, will go through this market opportunity with you. So, Ralph, please. Thank you very much, Petri.

Ralph Hughes
123:54 - 132:58

Thank you. Thank you for having me today. I wanted to spend a little bit of time today talking about the Bexmarilimab market opportunity and how Faron Pharmaceuticals sees the market opportunity for Bex as we move forward through the trials towards launch. The Myelodysplastic syndromes market is expected to grow significantly in the coming years. This is being driven by multiple factors. First of all, and probably most importantly, an aging population. Myelodysplastic syndromes is a disease of older patients. And that is important because we see the elderly population growing in Western markets. We are also seeing growth come from the launch of reformulations of Azacitidine and Decitabine, as well as from drugs in the lower-risk myelodysplastic syndromes market. However, all of these market projections are probably a significant underestimate of how the market will grow in the coming years because it does not include the enormous potential of a drug like bexmarilimab entering the market and seeing that market grow in a very significant and disruptive way. As we've heard many times, there have been no new treatments in this indication for the past 20 years. However, for the first time in a long time, we are now seeing multiple assets in early clinical development for HR-MDS. Many of these assets are, however, using previously failed modalities such as BCL-2 inhibitors and CD47. Faron Pharmaceuticals is actually one of the only companies bringing novel biology and a new biological approach to this space. And it's not just the new biology, but it's Faron Pharmaceuticals itself. By observing and learning, we are able to advance our clinical program, considering really important factors such as understanding how to deal with TP53, how to adapt the clinical trial numbers as a result of various interim analyses, and how to make sure we hit the right endpoints to meet the needs of our development plan. We at Faron Pharmaceuticals are viewing higher-risk MDS as the new multiple myeloma, an area of developmental difficulty that is now delivering excellent returns to investors. Delivering drugs to patients. And we really see Bexmarilimab as the head of a wave of new and exciting innovations in this space. Now, I thought it would be important to spend a little bit of time understanding how we at Faron Pharmaceuticals view the market potential for bexmarilimab. When we come to launch, we believe that the conditions will be incredibly favorable for bexmarilimab when we bring it to market. Drug pricing. This is a topic that is in the news a lot, and it's something that we spend a lot of time thinking about regarding what will happen when Bexmarilimab comes to the market. We have done extensive qualitative and quantitative research. So much of what I am about to talk about is based on that, but there are also many additional publications regarding this topic in terms of pricing. There are some established benchmarks in the field, such as Onureg, which is an oral azacitidine, which is essentially a branded oral version of an HMA, and that's priced around $25,000 per month in the US. That is about $300,000 per year. We also have Rytelo and Reblozyl, both assets in the lower-risk MDS space, and they are also priced similarly. And when tested with US payers, they will view these as a benchmark for an analog for our asset. However, in both of these situations, these are so in the Onureg situation, this is a reformulation of an existing asset. And in lower-risk MDS, these are drugs that treat anemia, not the underlying condition, and are therefore not disease-modifying. They are also launching into an area where there exist treatments already. So potentially a better analog, or an analog that's on a lot of people's minds at the moment, would be drugs in the very high unmet need space. Pancreatic cancer. This is an area where there have been no new launches for a long time. Extremely high unmet need. And here we see pricing of around $40,000 a month, which equates to about $480,000 per year in the United States. Another question that we get a lot and that I think is very interesting is epidemiology. As mentioned before, higher-risk MDS is a disease of older patients. Older patients; I think Amer earlier today said it was in patients around 70 years old. And that really matters because when we're talking about epidemiology, a lot of the published figures that are used very frequently are quite old and therefore do not reflect the demographics of an aging population. Certainly in Western markets, the US and Europe, we see the population aging, and as a result, the incidence of myelodysplastic syndromes (MDS) is increasing. So we conducted some internal analysis. We looked at all the publications out there on this, or the most commonly cited publications out there. And we updated them using today's demographics. And then we quality controlled and selected the most appropriate publications. The most appropriate publications. And here we end up with an epidemiology of around 5.3 per 100,000 incidence in the US and 6.3 per 100,000 in Europe. In terms of uptake, we did extensive qualitative and quantitative research. And as a result of that research, we have arrived at clear conclusions. We believe and we are predicting in our various models a very rapid uptake of around 4 to 5 years. And with a very high uptake in the region of 60% to 70% of the market share. So a very significant opportunity and a very favorable opportunity for Bexmarilimab when it ultimately comes to market. But the opportunity doesn't just stop there with Myelodysplastic syndromes, as we've heard from Petri and Doctor Serrano. We are also seeing massive potential to be unlocked by Faron Pharmaceuticals, or by Bexmarilimab, as a result of the additional studies that we are running. Soft tissue sarcoma is probably a population size not too dissimilar from higher-risk MDS and is potentially a quite similar market opportunity. We also have PD-1 refractory melanoma and non-small cell lung cancer, which potentially have much bigger market possibilities as well, both in terms of patient population and in terms of the dollar value of the market size as a whole. If we zoom the camera back a little bit and look at the biopharma deal-making sector as a whole, biopharma had a really tough year in 2024. In 2025, we saw a bit of a rebound back to normal levels of capital inflow and M&A. But in the first half of this year, 2026, we saw capital flooding back into the biotech sector. It is a good sector to invest in right now because of all the M&A that is going on at the moment. And in the first half of the year, we saw an absolutely bumper period in terms of that. So M&A is strong. Dealmaking is very active. And we are ready to take advantage of that when the moment comes. And we see this as a very exciting opportunity in terms of the market potential of Bexmarilimab. Thank you very much. Over to you. How do we take us out?

Juho Jalkanen
132:59 - 133:28

Let's have a little Q&A, just you and me, because this is a great slide, and I go out a lot to meet investors to see where the industry is. It seems to be thriving and it's beating general markets. The biotech market sector has been growing while other markets have been suffering from the ongoing geopolitical climate. But biotech has been protected from that for some reason. How do you feel about that?

Ralph Hughes
133:28 - 134:10

Well, I think it is interesting. I mean, we look at 2024 as a very rough year. And I think that meant that there was quite a bit of dry powder still around. And therefore, there was a lot of activity and a lot of hunger to do a lot of deals. I think there were also some companies that could not survive and likely went under. And so we saw the cream rising to the top. I suppose the better companies or the companies that really have true value to add are surviving. And I think that is a large part of why we saw such an extraordinary amount of M&A happening in the first part of this year.

Juho Jalkanen
134:11 - 134:55

Wonderful. Thanks. Another question or topic I really want to dive into, which I've seen in the past, especially from a physician's lens, is that when you go into an indication where there is really not much available, like high-risk Myelodysplastic syndromes, especially relapsed/refractory Myelodysplastic syndromes, where there is absolutely nothing, the market is usually underestimated and people are even left without treatment or without diagnosis because there is simply nothing. So, how do you feel? Is that somewhat reflected in your numbers or our numbers? Or how do you see the relapsed/refractory and frontline populations; are they underestimated?

Ralph Hughes
134:55 - 136:42

That is a brilliant question. And I spent a large part of my career both at Pfizer, Mundipharma and Pharma Ventures, modeling indications and trying to figure out the distribution between different indications and sub-indications, and how different launches at different times affect these things. I think you raise a really good point. I mean, I think when you have an area of very high unmet need, what you often see is clinicians very keen to use medicine that is new and coming into a market. So, in a situation like this where we have a relapsed refractory population and a frontline population, one would predict a heavy overlap between the two. And if you have an approval in one indication, and it is very close, you would expect a certain amount of cannibalization of one indication from the other. A massive amount of overlap into the other indication as well. So, I think generally market estimations are probably an underestimation in this space. We have seen it time and time again when you have not had anything and you have all this pent-up enthusiasm from clinicians to use a drug in a space. So, I think that is part of the reason why we had such strong feedback during our quantitative research. Actually, the numbers that we are predicting are slightly lower than what the KOLs wanted because we are trying to be cautious and realistic. Yeah. So I think it is important for us to be a little conservative, but yes, I would say this is probably an underestimate.

Juho Jalkanen
136:42 - 143:58

Wonderful. Thanks a lot, Ralph. Thanks for being here. And on we go. So, if you've made it almost to the very end, this is how I boil all this down. We have seen a lot. We have heard a lot. But I am a simple-minded guy. And I think the first question is, how did a practicing physician join a biotech? It is because of cancer. And eventually cancer will profoundly touch us all, if not ourselves, a loved one, a family member, or somebody we know. When it does that, it will leave a permanent mark. I have experienced that myself. And this has given me the drive and the energy to go further and explore further. We need to do more. Cancer continues to kill. We need to solve this problem. I do not take no for an answer. But why does cancer still kill? We have made great advances. PD-1 checkpoint inhibitors. Now the new developments in pancreatic cancer. Amazing. Absolutely amazing. We have hundreds and hundreds of treatments. A lot of studies are going on. But why does cancer still kill? It's because of treatment resistance. It is what our CSO, Maija Hollmén, talked about; a key cell in treatment resistance is the macrophage or the myeloid cell. They are basically the same thing. We are going to talk about macrophages here. And this is not just us saying it. You can go look at it in literature. The literature is full of it. Macrophages remain the key source of treatment resistance as Maija pointed out. Usually, 50% of a non-responsive tumor is made of macrophages. And I have talked a lot about this with pharma. And pharma says, "Oh, macrophages." They are so difficult. They do not seem to work. And I am asking, are we just going to go around and pretend that they are not there? No. At least not me. I cannot live my life that way. So, something has to be done for the macrophages. And we've worked in this field for over two decades. This is writing new biology. AI will never write us new biology. What the patients and the pharma industry actually need are new targets. AI will not give them to us. So, understanding the biology of Clever-1 and how to tackle it is a result of over 20 years of simple, old-fashioned hard work. It does not come easy, does it? AI is good at designing and characterizing molecules, but again, it does not give us new targets. It requires good, old-fashioned science, understanding, and writing new biology. We have learned that Clever-1 is essential for targeting macrophages or trying to make them work for us. And to tackle Clever-1, we have bexmarilimab, the first-in-class Clever-1 antibody, which again has, in our belief, the best-in-class activity and safety when targeting macrophages. Again, a lot of strategies have been tried to target macrophages. Unfortunately, they have not been that successful. But so far what we see is that this has the best-in-class profile. We are focusing on activity and safety when targeting macrophages. So, what is our vision? We aim to establish bexmarilimab as the cornerstone of cancer care in cancers where Clever-1 positive macrophages are the source of treatment resistance and cancer progression. That is a bold statement, but that is what we want to do. What does this actually mean? Well, how many patients, what kind of cancers? Basically, simplifying this means that we could, if successful, be able to help around 20% to 30% of patients suffering from treatment resistance. That is based on screening biobank data, which shows that roughly cancers vary on how Clever-1 positive they are. But that is our bullish estimate. But then again, we have to be realistic. We are a small biotech. How are we going to accomplish this? Everything starts with focus. So this is what I call the 'how to eat the elephant' slide. We are prioritizing all our resources where we see the best bet and the biggest need. And that is high-risk myelodysplastic syndromes. Myelodysplastic syndromes. Because everyone is Clever-1 positive. Excellent results. It presents a lower bar, possibly for accelerated approval. Meanwhile, given our resources and by working with world-leading clinical research organizations and CDMOs, we are expanding into new areas where assets are shared. The low-hanging fruits may be indications like sarcoma, checkpoint-refractory melanoma, and lung cancer. So we're expanding again as much as we can. Currently, we are receiving more investigator-initiated trial proposals than we can handle at the moment. And unfortunately, we cannot sponsor them all. Eventually, as we generate revenue through the myelodysplastic syndromes program, we will start converting these other investigator-initiated trials into company-sponsored trials and push them toward approval as well within our resources. Again, all of what we are doing will then result in what we believe is significant shareholder value, including the data we have been looking at today. We will be producing data throughout 2027 from not one, not two, not three, but four, and possibly even five, new indications. Now show me another biotech that's going to do all this with the resources and size of us. So that's what we're made of. We are here to tackle macrophages in cancer. Thank you. So now we are going to invite the management back and take a few questions from the audience. I hope you stayed awake until the very end and have typed a lot of questions in. Come on team.

Unknown 1
144:04 - 144:21

Thank you. You know, there are plenty of questions, but let's take the first one, as there are a few questions about partnering. Could you please elaborate on the current partnering situation for bexmarilimab?

Ralph Hughes
144:22 - 144:45

Thank you. Yes. Good question. Like any biotech, we are engaged in regular and ongoing dialogues with various partners of different types. Certainly, this is something that we are exploring very openly, and we are very keen to ensure that we have good partners as we move the program forward.

Unknown 1
144:47 - 144:59

Thank you. And then the next question is regarding the uptake for Bexmarilimab. What uptake do you estimate in high-risk Myelodysplastic syndromes and what supports this estimate for uptake?

Ralph Hughes
145:00 - 146:19

So in high-risk myelodysplastic syndromes, we estimate around 60% to 70% in frontline, and similar in relapsed/refractory settings. However, relapsed/refractory based on the current plan would be an overspill or essentially a result of a certain cannibalization of the second-line market as a result of that. That is based on extensive quantitative research that we have done both in the US and in Europe. We predict that uptake to take around 4 to 5 years to reach peak. Obviously, price growth, inflation, and so on will continue to see additional growth. But in terms of the actual pure market share, that is where we would put it. There is also the aging population, which is another factor within there; as I've talked about, it is a very real effect because the incidence in the general population is around 5.3% to 6.3%. But the moment that you look at patients over 65, it shoots up by about tenfold. So it is a very significant factor in any kind of forecast modeling.

Unknown 1
146:20 - 146:36

Thank you. And I believe this next one goes for Petri. How widely accepted is complete response as an endpoint in high-risk myelodysplastic syndromes? And has the field's view changed regarding these endpoints?

Petri Bono
146:37 - 147:26

Thank you. Excellent question. The FDA published a guidance for the industry. A year ago, in the guidance, they officially stated that complete remission plus partial remission is a valid endpoint in high-risk myelodysplastic syndromes for durable CR. And it's not just the regulatory agencies, but also clinicians and key investigators who feel the same way that overall survival (OS) is not the only endpoint we need to look at. That approval should be based on durable CR. Of course, at the same time, we need to show that there is no detrimental effect on OS when you produce a high rate of durable CRs.

Unknown 1
147:26 - 147:42

Thank you. And the next question is about single-agent activity. Bexmarilimab has not been tested as a single agent in the frontline setting. Why should investors still be confident in it, Juho?

Maija Hollmén
147:43 - 148:30

I can take that first, perhaps. It has now been tested as a single agent in the last-line setting. And there you have a very high tumor burden and metastatic disease. And what we know about immunotherapies is that they usually work better when the tumor load is lower. That is true even for anti-PD-1, for example. So, therefore, I believe that the closer you are to the first-line setting, the better responses you get. And also, these patients in the first-line setting have not been treated with all the lymphodepleting therapies. Their bone marrows are not exhausted. So they have a better ability to have anti-tumor responses because they have higher levels of adaptive immune cells like lymphocytes. And this is why I believe that it would work very nicely in the first-line setting. Does anybody else want to add anything?

Juho Jalkanen
148:30 - 149:03

Yeah. Maybe to also add, because again when disease burden is very high, for example, if we're thinking MDS to AML, disease burden is already very high in AML and we know that Bexmarilimab is not a cytotoxic agent. Hence the relatively good safety profile. So, Bexmarilimab as a single agent could be very effective in low disease burden settings, but again, in high disease burden settings where you ultimately start drug development, it is not the most optimal situation.

Petri Bono
149:04 - 149:40

Petri dishes were the most important ones, but in the clinics with PD-1 inhibitors, it has been shown in multiple tumor types that you do not get good efficacy in late-stage or late-line treatments, so you get the optimal results not just in the frontline treatment of metastatic patients, but the best results, for example, in melanoma, are in the neoadjuvant setting before surgery. So, I think that tells everything, and there is no reason to believe, based on what just Maija told us, that it would be different with bexmarilimab. Thank you.

Unknown 1
149:40 - 149:58

And a few questions about BEXERA timing and also have there been any surprises? But first, when do you expect the first patient to be enrolled in the BEXERA trial? And is everything according to the timelines that we have communicated previously?

Petri Bono
149:59 - 150:15

Maybe I can take this. We are progressing well. We have already stated that the first patient will be treated in Q4, as Amer Zeidan showed in his slide. So, first sites are opening now in October, and we are well on track and we expect the first patient to be treated soon.

Unknown 1
150:17 - 150:25

Thank you. And as a follow-up, have there been any surprises since we started the BEXERA trial and the preparations for that?

Petri Bono
150:26 - 150:48

We have a superb CRO that we are working with. Parexel. And, of course, they are an experienced CRO. So, we have surprises all the time every week, but we tackle them little by little every day. And as I just mentioned. So we are very well on track to get the first patient treated soon.

Unknown 1
150:50 - 151:10

Thank you. And about the mode of action, the mechanism of action is very novel. Given that there have been a lot of setbacks in the field of macrophage targeting. What gives you the confidence that Clever-1 as a target will continue to stand out, Maija Hollmén?

Maija Hollmén
151:11 - 151:47

Yeah. So we have a very novel mode of action. And as I mentioned in my talk and when we were doing the Q&A previously, I believe that Clever-1 is a non-redundant molecule on macrophages. And what we have seen in the lab is that if we block Clever-1 with bexmarilimab, we see a downregulation of other checkpoints. This is on the T cells and on macrophages. So we are effectively downregulating those that are already inhibited by other drugs. So with one drug, we can accomplish this, meaning that we have a very good safety profile, while achieving the beneficial effects on a macrophage to support anti-tumor responses.

Juho Jalkanen
151:49 - 151:51

And I would just say it is a master regulator.

Petri Bono
151:52 - 152:27

And maybe I can add a comment here. Although we discussed that the last-line patients were treated in the trial. We are going to have the overall survival results from the melanoma cohort with 25 patients. The overall survival update of those patients, even though 100% of them were PD-1 refractory, remains encouraging. So, I think it nicely shows the encouraging activity that we see with a single agent, even in late-stage tumors.

Unknown 1
152:28 - 152:36

Yeah. There was also a question about the melanoma results that were seen in the mid-teens.

Petri Bono
152:36 - 153:06

The most important result is related to overall survival, and they are currently under embargo. But in two weeks, we will present them. But they are very positive. Thank you. There will also be translational data showing how the tumor microenvironment is impacted. The cytokine environment also has an impact on the outcome of the patients when they are treated with BEXMAB, which fits very nicely with the mechanism of action that we showed in the trial.

Unknown 1
153:07 - 153:19

Thank you. And have you observed any differences in Clever-1 expression between patients who responded to bexmarilimab and those who didn't?

Maija Hollmén
153:20 - 153:43

So this was something that Petri already mentioned in his talk; the biomarker studies we conducted showed that patients who achieved a response in the trial had higher levels of intratumoral Clever-1 positive macrophages. So, it seems to matter how many of them you have. And therefore, we are looking at perhaps using that in future trials to enrich patients based on Clever-1 histology.

Petri Bono
153:43 - 154:11

And from BEXERA, we will get extremely important validation. What we saw in the MATINS study. And after that, hopefully, we will be able to also start using selection criteria. There are quite strict regulations. What is the ready test to be used for patient selection in a prospective formal clinical trial. So we need to validate the results of the biomarker in these upcoming trials.

Juho Jalkanen
154:12 - 155:01

Maybe to chime in here again for the audience. MATINS was the first-in-human study in solid tumors as a single-agent treatment. And again, how we see it is that the patients who had Clever-1 positive macrophages received the clinical benefit. And again, when you look at large, heterogeneous solid tumors like breast or lung cancer, patient selection will ultimately be needed. Patient selection will ultimately be needed. But for example, we know in melanoma that PD-1 resistant patients are more abundant with Clever-1. And then in sarcoma, as César Serrano noted. So it is a very Clever-1 high cancer. So we will look to establish possibly a threshold for patient selection. Whether one will be needed, for example in sarcoma, remains to be seen. And that is why this study is also super important to learn that.

Unknown 1
155:04 - 155:23

Thank you. We have quite scientific questions, maybe for Maija. Do you have evidence that bexmarilimab restores normal hematopoiesis independently of blast reduction, or could the observed recovery simply be a consequence of disease control?

Maija Hollmén
155:24 - 156:02

This observation and the resulting hypothesis are based on mouse experiments that we have conducted in the lab. We treated the mice with 5-fluorouracil for one dose and then looked at the recovery after anti-Clever-1 blocking. And if we block Clever-1 in these mice, they have much improved, faster recovery of platelets, lymphocytes, and granulocytes. So it seems to hold true, at least in our models, that it can induce hematopoietic recovery regardless of blast count. And these mice that we were using in our experimentation were healthy mice. So they did not have tumors.

Unknown 1
156:04 - 156:14

Thank you. And the next question for you. Could you please remind us of the status of the CMC production, where we are today?

Juho Jalkanen
156:15 - 156:32

Yes, absolutely. We are very well on track with that. We are already at a commercial scale of 2000 liters with a robust process representing what we believe to be the commercial manufacturing process. We are well-positioned in that regard.

Unknown 1
156:34 - 156:47

Thank you. And as a last open question to all of you, what are you waiting for most next? What are the reasons why you are excited, what data are you expecting, and so on.

Juho Jalkanen
156:48 - 156:50

I'm going to let the team go first. I will go last.

Maija Hollmén
156:50 - 157:17

I can go first. I'm really waiting to see the contribution of components in the BEXERA trial. I have been asking for quite many years to see a single-arm study, or the use of bexmarilimab alone in myelodysplastic syndromes, to scientifically compare what bexmarilimab can do in the disease. But now we are getting the placebo control. So I am really waiting for the patient data that we will be getting and the analysis of that data.

Petri Bono
157:19 - 158:26

And maybe to continue, of course, BEXERA results are super exciting. That is the final proof of concept that in a randomized setting, the benefit for the patients is coming from the addition of bexmarilimab. But of course, I am a solid tumor expert, so I look forward to the data from the IITs and the BEXERA trial to see if we can overcome resistance in solid tumors. Even one good deep response among the first ten patients is a clear sign to proceed. And then also, we didn't talk that much about BEXERA, but we know the hematopoiesis effect very well with single-agent azacitidine, how deep neutropenia patients develop, how long-lasting neutropenia they have, and then how many infections requiring hospitalization they have. So all these data points we will gather from the combination of doxorubicin plus bexmarilimab. And of course, we believe that in addition to BEXERA, from that trial, we can show that the benefit for the patients from the increased hematopoiesis is a true phenomenon.

Ralph Hughes
158:27 - 158:51

And I think obviously BEXERA is. The readout is incredibly exciting, but I am completely convinced that it is going to be positive, that actually I, like Petri, am most excited about how big this opportunity can get, how these additional solid tumor trials will allow us to expand into new indications and help new patients.

Juho Jalkanen
158:52 - 159:47

Well, that is well said. I like to talk. So, maybe I will say what I feel, actually from a physician perspective, I am absolutely—it is kind of crazy—but I am looking at the safety in BEXERA, for example, because when we started seeing that, hey, the safety profile looks better than with single-agent Azacitidine, everybody was saying, yeah, right. Yeah. Well, efficacy is the key factor. No, but imagine if we have the efficacy and we even improve on safety, and now it is going to be really tested against single-agent Azacitidine. If that is present, it is an amazing drug, and I am really thrilled about that. And then ultimately, what I'm super excited about, like I mentioned, is that 20 years of work is now being put to the bench, and we'll see what the opportunity is for Clever-1. How many patients and which cancers; it is all coming together.

Unknown 1
159:50 - 159:52

Thank you for all the questions.

Juho Jalkanen
159:54 - 160:13

All right, then. Well then, that was a very good discussion. Closing remarks: 20 years of research brought from the bench to a randomized trial. Here we go, everybody. Super exciting times. Stay tuned.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…